Glycosylate derivatives of mithramycin, method of preparation and uses thereof

ABSTRACT

The present invention provides compounds characterized by the formula (I), where each of the substituent radicals is described in the specification. The invention also describes the use of said compounds in the treatment of various diseases, including: cancer or tumoral processes in general, Paget&#39;s disease, hypercalcaemia, hypercalciuria and neurological diseases (inter alia, Parkinson&#39;s, Alzheimer&#39;s, Huntington&#39;s).

The invention belongs to the pharmaceutical field and specificallyrelates to compounds with application in oncology, with a chemicalstructure derived from mithramycin and which are obtained bymicroorganism fermentation.

STATE OF THE ART

Mithramycin (MTM) is an antitumor drug produced by microorganisms of theStreptomyces genus, including Streptomyces argillaceus ATCC 12956. Thisdrug is the most important representative of the group of aureolic acid,and it is used for the treatment of testicular carcinoma, Paget'sdisease and hypercalcaemia caused by bone lesions associated to cancer(Oncology 1973, 28,147-163; Biochem. Biophys. Res. Commun. 1993, 195,1245-1253; Treat. Endocrinol. 2002, 1, 241-257; Treat. Endocrinol. 2003,2, 273-292). MTM is furthermore a neuroprotective agent which could beuseful for the treatment of neurological diseases such as stroke,amyotrophic lateral sclerosis, Parkinson's disease, Huntington'sdisease, multiple sclerosis and viral encephalitis (J. Neurosci. 2004,24, 10335-10342; J. Biol. Chem. 2006, 281, 16672-16680). Furthermore,MTM has antibiotic activity (Antibiot. Chemother. 1962, 12, 182-186).

The chemical structure of MTM is shown in FIG. 1. The group of aureolicacid compounds includes MTM, chromomycin A₃, olivomycin A, UCH9 andduramycin (Appl. Microbiol. Biotechnol. 2006, 73, 1-14). All of themcontain a tricyclic core with a polyketide origin, with a highlyfunctionalized side chain at carbon 3. The residue at carbon 7 can be ahydrogen atom or a short-chain alkyl. Likewise, these compounds have 4-6deoxysugars linked in the form of trisaccharide or tetrasaccharide (atcarbon 2) and monosaccharide or disaccharide (at carbon 6). Aureolicacid compounds differ in the nature and linking of their saccharidechains, containing different 2,6-dideoxysugars. These structuralvariations are responsible for the subtle differences existing among themembers of the group as regards their DNA binding and their biologicalactivity profile. It is well known that the glycosylation pattern ofantitumor drugs which act by binding to DNA, as is the case of MTM, isvery important in their biological activity (Biopolymers 2000, 54,104-114). Therefore, obtaining novel derivatives of MTM with alteredglycosidic patterns can generate drugs with improved activity. Thecluster of genes responsible for M™ biosynthesis has been widely studied(Appl. Microbiol. Biotechnol. 2006, 73, 1-14). MTM biosynthesis inStreptomyces argillaceus includes the condensation of 10 units ofacyl-coenzyme A to generate a tetracyclic intermediate, calledpremithramycinone (FIG. 2). Then, 5 units of deoxysugars aresuccessively added, tetracyclic intermediates with 3 sugars and with 5sugars being generated. The glycosyltransferases MtmGIII and MtmGIV areresponsible for the formation of the trisaccharide, whereasglycosyltransferases MtmGI and MtmGII catalyze the formation of thedisaccharide. Finally, the cleavage of one of the rings, followed by thereduction of a keto group in the side chain, generates MTM.

There is currently a great need for novel antitumor agents, withimproved activity, with fewer undesirable side effects and with higherselectivity, compared to currently used drugs. Traditionally, thepharmaceutical industry has developed novel drugs by means of two mainroutes: (1) search for novel natural products, and (2) chemicalmodification and/or synthesis of certain compounds. These methods arestill useful, but usually require very important investments ofresources (time, money, energy), since it is normally necessary toanalyze thousands of products in order to find a novel promisingcompound. The development of recombinant DNA technology has opened up aninteresting field of research for the generation of novel bioactivecompounds by means of the manipulation of genes involved in thebiosynthesis of antitumor agents, mainly of bacteria of the actinomycetegroup (Trends Biotechnol. 2001, 19, 449-456; J. Mol. Microbiol.Biotechnol. 2005, 9, 77-85; Curr. Opin. Drug Discov. Devel. 2005, 8,748-756; J. Ind. Microbiol. Biotechnol. 2006, 33, 560-568; Curr. Opin.Microbiol. 2006, 9, 252-260). These techniques can also be used toimprove the production of already known natural compounds, since naturalstrains usually produce low concentrations of the metabolite ofinterest.

DESCRIPTION OF THE INVENTION

The present invention provides novel bacterial strains derived fromStreptomyces argillaceus. These strains are obtained by means ofintroducing certain additional nucleic acids in existing bacterialstrains, which can be: (a) Streptomyces argillaceus, or (b) strainsderived from Streptomyces argillaceus. The strains of section (b) can beobtained (among other methods) by means of the inactivation of one (orseveral) of the genes responsible for mithramycin biosynthesis, and areuseful for obtaining derivatives of MTM (US 2005/0192432 A1; J. Am.Chem. Soc. 2003, 125, 5745-5753; J. Am. Chem. Soc. 2002, 124, 1606-1614;Mol. Gene. Genet. 2001, 264, 827-835; FEMS Microbiol. Lett. 2000, 186,61-65; Mol. Gene. Genet. 2000, 262, 991-1000; J. Biol. Chem. 2000, 275,3065-3074; Mol. Gene. Genet. 1999, 261, 216-225; Chem. Biol. 1999, 6,19-30; J. Bacteriol. 1999, 181, 642-647; J. Bacteriol. 1998, 180,4929-4937; J. Bacteriol. 1997, 179, 3354-3357; Mol. Gene. Genet. 1996,251, 692-698; Gene 1996, 172, 87-91). An example of strain of section(b), which can be used in the present invention, is Streptomycesargillaceus M7U1, which was obtained from Streptomyces argillaceus bymeans of the inactivation of the mtmU gene (Mol. Gene. Genet. 2001, 264,827-835). The mtmU gene encodes a 4-ketoreductase involved in D-oliosebiosynthesis, and its inactivation results in the accumulation ofpremithramycinone and premithramycin A. Another example of strain ofsection (b) is Streptomyces argillaceus M7W1, which was obtained fromStreptomyces argillaceus by means of the inactivation of the mtmW gene(US 2005/0192432 A1; J. Am. Chem. Soc. 2003, 125, 5745-5753). The mtmWgene encodes a ketoreductase, and its inactivation results in theaccumulation of demycarosyl-MTM-SK, MTM-SA, MTM-SDK, and MTM-SK.

The introduction of nucleic acids in Streptomyces argillaceus (or inderivative strains) can be carried out by means of protoplasttransformation, conjugation, or other known methods (such as thosedescribed in Practical Streptomyces genetics, The John Innes Foundation,Norwich, Great Britain, 2000), such that the nucleic acids arereplicable in the organism, either in the form of an extrachromosomalelement or integrated in the chromosome of the organism. Said nucleicacids encode enzymes for the biosynthesis of different sugars; saidsugars are not normally produced by Streptomyces argillaceus. Examplesof nucleic acids useful for the present invention are those contained inthe following plasmids (which are mentioned by way of example): pLNBIV(Chem. Biol. 2002, 9, 721-729; J. Nat. Prod. 2002, 65, 1685-1689), pRHAM(J. Mol. Microbiol. Biotechnol. 2000, 2, 271-276), pLN2 (Chem. Biol.2002, 9, 721-729), pLNR (Chem. Biol. 2002, 9, 721-729), and pFL845(Chem. Commun. (Camb). 2005 Mar. 28; (12):1604-6). The mentionedplasmids contain nucleic acids encoding enzymes for the biosynthesis ofthe following sugars (in the form of NDP derivatives), respectively:L-digitoxose, L-rhamnose, L-olivose, D-olivose, and D-amicetose.However, other nucleic acids which encode enzymes for the biosynthesisof other unmentioned sugars can be used in the present invention.

The bacterial strains of this invention can be cultured in any suitablemedium, in conditions allowing their growth, as is described in Gene1996, 172, 87-91; J. Bacteriol. 1998, 180, 4929-4937; J. Am. Chem. Soc.2003, 125, 5745-5753. After several days of incubation, these culturescontain a high amount of cells (mycelium), together with a mixture ofcompounds, including derivatives of MTM. The cultures are then subjectedto processes for the separation of a liquid phase (supernatant) and asolid phase (mycelium). The two phases are then subjected, separately,to several processes which can include extraction with several organicsolvents, and several types of chromatography (such as HPLC, highperformance liquid chromatography), for the purpose of obtaining thederivatives of MTM in the form of pure compounds. The derivatives of MTMare antitumor agents and also act as neuroprotective agents.

Likewise, the present invention provides compounds characterized by thefollowing formula (I):

whereinR₁ is hydrogen, hydroxyl (OH), a hydroxyl group protected with aprotecting group, a monosaccharide of formula (II)

R₂ is hydrogen, a protecting group, a monosaccharide of formula (III),

a monosaccharide of formula (IV),

a disaccharide of formula (V),

a disaccharide of formula (VI),

or a disaccharide of formula (VII).

a monosaccharide of formula (XIV),

a disaccharide of formula (XV),

or a disaccharide of formula (XVI)

R₃, R₄, R₅, R₆, R₇ and R₈, R₁₀, R₁₁, R₁₂, R₁₃, R₁₄, R₁₅, R₁₆, R₁₇,R₁₈, R₁₉, R₂₀, R₂₁, R₂₂, R₂₃ and R₂₄, R₂₅, R₂₆, R₂₇, R₂₈, R₂₉, R₃₀, R₃₁are each and independently hydrogen or a protecting group; R₉ ishydrogen, a methyl group, or an alkyl group; and the stereochemistry ofcarbons a, b, c, d and e is R, S or a mixture of both.

The protecting group can consist of an alkyl group, a cycloalkyl group,a heterocyclic cycloalkyl group, a hydroxyalkyl group, a halogenatedalkyl group, an alkoxyalkyl group, an alkenyl group, an alkynyl group,an aryl group, a heterocyclic aryl group, an alkylaryl group, an estergroup, a carbonate group, a carboxylic acid group, an aldehyde group, aketone group, a urethane group, a silyl group, a sulfoxo group or acombination thereof.

The compounds of formula (I) include those wherein:

R₃, R₄, R₅ and R₆ are hydrogen; or

R₃, R₄, R₅, R₆, R₇ and R₈ are hydrogen; or

R₉ is methyl; or

the stereochemistry at carbons a, b, c and d is S, and thestereochemistry at carbon e is R; or

R₃, R₄, R₅, R₆, R₇, R₈, R₁₀, R₁₁, R₁₂, R₁₃, R₁₄, R₁₅, R₁₆, R₁₇, R₁₈, andR₁₉, R₂₀, R₂₁, R₂₂, R₂₃, R₂₄, R₂₅, R₂₆, R₂₇, R₂₈, R₂₉, R₃₀, R₃₁ arehydrogen, R₉ is methyl, the stereochemistry at carbons a, b, c and d isS, and the stereochemistry at carbon e is R.

In particular, the present invention provides, among others, thecompounds with the following formulas (VIII, IX, X, XI, XII, XIII):

The compounds of the invention are tumor growth inhibitors and aretherefore useful in the treatment of cancer.

Thus, the pharmaceutical compositions comprising an effective amount ofa compound of formula I or a pharmaceutically acceptable salt or solvatethereof together with a pharmaceutically acceptable excipient are objectof the present invention.

The use of a compound of formula I or a pharmaceutically acceptable saltor solvate thereof in the manufacture of a medicinal product is alsoobject of the present invention.

The use of a compound of formula I or a pharmaceutically acceptable saltor solvate thereof for inhibiting the growth of a tumor is also objectof the present invention.

As used herein, “inhibiting” means decreasing, slowing down or stopping.Therefore, a compound of this invention can decrease, slow down or stopthe growth of a tumor cell. As used herein, “growth” means increase insize or proliferation or both. Therefore, a compound of this inventioncan inhibit the size increase of a tumor cell and/or can prevent thetumor cell from dividing and the number of tumor cells from increasing.A “tumor cell” is a cell forming a neoplasm (new growth), which can becancerous (malignant) or non-cancerous (benign). A cancerous tumor cellcan invade the normal tissues around it and blood/lymph vessels and formmetastases in tissues far from the original tumor. In contrast, anon-cancerous tumor cell can grow and compress adjacent normal tissuesbut cannot invade normal tissues and blood/lymph vessels and cannot formmetastases in tissues far from the original tumor.

The use of a compound of formula I or a pharmaceutically acceptable saltor solvate thereof for treating cancer is also object of the presentinvention.

The use of a compound of formula I or a pharmaceutically acceptable saltor solvate thereof in the manufacture of a medicinal product withantitumor activity is also object of the present invention.

The use of a compound of formula I or a pharmaceutically acceptable saltor solvate thereof in the manufacture of a medicinal product for thetreatment of cancer is also object of the present invention.

A method for treating a subject, including a human being, diagnosed withcancer, consisting of treating said subject with a therapeuticallyeffective amount of a compound of formula I or a pharmaceuticallyacceptable salt or solvate is also object of the present invention.

As used herein, a “subject” can include domesticated animals (forexample, cats, dogs, etc.), livestock (for example, cows, horses, pigs,sheep, goats, etc.), laboratory animals (for example, mice, rabbits,guinea pigs, etc.) and birds. The subject is preferably a mammal such asa primate, and, more preferably, a human being.

In general, an “effective amount” of a compound is that amount necessaryto achieve the desired result. For example, the effective amount of acompound of the present invention treats the cancer by inhibiting thegrowth of the cells forming the tumor, thereby preventing invasion ofnormal tissues and blood/lymph vessels by the tumor cells and, thereforepreventing metastasis. Examples of cancers that can be treated include,but are not limited to, lung, colon, ovarian, prostate, testicular,melanoma, kidney, breast, central nervous system and leukemia. Theexpression “acceptable pharmaceutical composition” consists of abiologically suitable material, i.e., the material may be administeredto the subject without causing substantially deleterious biologicaleffects.

The doses or amounts of the compounds of the invention must besufficiently large to cause the desired effect. However, the dose mustnot be so large that it causes adverse side effects, for exampleunwanted cross-reactions, anaphylactic reactions, and the like.Generally, the dose will vary with age, condition, sex and the degree ofdisease of the subject, and can be determined by any person skilled inthe art. The dose can be adjusted by each physician, based on theclinical condition of the subject involved. The dose, dosing regimen androute of administration can be varied. The doses and the dosing regimencurrently used for MTM provide a guideline for the doses and dosingregimen that can be used for the novel derivatives of MTM (see forexample Cancer Treat. Rep. 1979, 63, 1835-1838; Ann. Intern. Med. 1975,83, 659-660).

The use of a compound of formula I or a pharmaceutically acceptable saltor solvate thereof in the manufacture of a medicinal product for thetreatment of Paget's disease is also object of the present invention.

A method for treating a subject, including a human being, diagnosed withPaget's disease, consisting of treating said subject with atherapeutically effective amount of a compound of formula I or apharmaceutically acceptable salt or solvate is also object of thepresent invention. The subject can be a mammal, preferably a humanbeing, and the compound can be, among other routes, parenterallyadministered.

The use of a compound of formula I or a pharmaceutically acceptable saltor solvate thereof in the manufacture of a medicinal product for thetreatment of hypercalcaemia is also object of the present invention.

A method for treating a subject, including a human being, diagnosed withhypercalcaemia, consisting of treating said subject with atherapeutically effective amount of a compound of formula I or apharmaceutically acceptable salt or solvate is also object of thepresent invention. The subject can be a mammal, preferably a humanbeing, and the compound can be, among other routes, parenterallyadministered.

The use of a compound of formula I or a pharmaceutically acceptable saltor solvate thereof in the manufacture of a medicinal product for thetreatment of hypercalciuria is also object of the present invention.

A method for treating a subject, including a human being, diagnosed withhypercalciuria, consisting of treating said subject with atherapeutically effective amount of a compound of formula I or apharmaceutically acceptable salt or solvate is also object of thepresent invention. The subject can be a mammal, preferably a humanbeing, and the compound can be, among other routes, parenterallyadministered.

The use of a compound of formula I or a pharmaceutically acceptable saltor solvate thereof in the manufacture of a medicinal product for thetreatment of neurological diseases is also object of the presentinvention.

A method for treating a subject, including a human being, diagnosed witha neurological disease, consisting of treating said subject with atherapeutically effective amount of a compound of formula I or apharmaceutically acceptable salt or solvate is also object of thepresent invention. The subject can be a mammal, preferably a humanbeing, and the compound can be, among other routes, parenterallyadministered.

Examples of neurological diseases that can be treated include, but arenot limited to, neurodegenerative diseases such as Parkinson's,Alzheimer's, and Huntington's diseases.

The compounds of the invention can be useful for the research inbiochemistry or cell biology. For example, the compounds can be usefulfor blocking the expression of c-Src (and other Sp1-dependent enzymes)in osteoclasts or other cell types.

Any of the compounds of the invention can be therapeutically usedforming part of an acceptable pharmaceutical composition. Any personskilled in the art can create acceptable pharmaceutical compositions,which may consist of sterile water solutions, saline solutions, orbuffered solutions at physiological pH. Any of the compounds of theinvention can be prepared in the form of pharmaceutical composition. Thepharmaceutical compositions may include several carrier agents,thickeners, diluents, buffers, preservatives, surfactants, and others,in addition to the compound of the invention. The pharmaceuticalcompositions may also include active ingredients such as antimicrobialagents, anti-inflammatory agents, anesthetic agents, etc.

The compounds of the invention can be administered to the subject inseveral different ways depending on whether the treatment is to be localor systemic, and depending on the area to be treated. Thus, for example,a compound of the present invention can be administered in the form ofophthalmic solution, for application in the surface of the eye.Furthermore, a compound can be administered to a subject vaginally,rectally, intranasally, orally, by inhalation, or parenterally, byintradermal, subcutaneous, intramuscular, intraperitoneal, intrarectal,intra-arterial, intralymphatic, intravenous, intrathecal andintratracheal routes. Parental administration, if used, is generallycarried out by means of injection. Injectables can be prepared indifferent forms, such as liquid solutions or suspensions, solid formssuitable for being dissolved or suspended prior to injection, or asemulsions. Other forms of parenteral administration use slow orsustained release systems, such that a constant dose is maintained (see,for example, U.S. Pat. No. 3,710,795). Preparations for parenteraladministration include sterile aqueous or non-aqueous solutions,suspensions, and emulsions which may further contain buffers and diluentadditives and others. Examples of non-aqueous solvents are: propyleneglycol, polyethylene glycol, vegetable oils such as olive oil, andinjectable organic esters such as ethyl oleate. Examples of aqueoussolvents are: water, alcoholic-aqueous solutions, emulsions orsuspensions, including saline and buffered solutions. Examples ofparenteral vehicles are: sodium chloride solution, Ringer's dextrose,dextrose and sodium chloride, etc. Preservatives and other additivessuch as, for example, antimicrobial agents, anti-oxidants, chelatingagents, inert gases, etc may also be present. Formulations for topicaladministration may include creams, lotions, gels, drops, suppositories,sprays, liquids and powders. Certain conventional pharmaceuticalcarriers, aqueous, oily or powder bases, thickeners, etc. may also benecessary or desirable. Compositions for oral administration may includepowders or granules, suspensions or solutions in water or non-aqueousmedium, capsules or tablets. The inclusion of thickeners, flavorings,diluents, emulsifiers, dispersants, etc. may be desirable.

For the purposes of the present invention and its description, the term“derivative” of mithramycin must be interpreted as a compound covered bythe general formula I. Likewise, the term “prodrug” of mithramycin mustbe interpreted, for the purposes of the present invention and of thedescription thereof, as any compound releasing mithramycin or aderivative, according to general formula I, thereof when it circulatesin blood or enters the cell.

DESCRIPTION OF A PREFERRED EMBODIMENT

The following examples, described in detail, are set forth in order tobetter understand the present invention, which examples must beunderstood without a limiting character for the scope of the invention.

Example 1 Obtaining the Bacterial Strain Streptomyces argillaceus(pLNBIV)

The strain Streptomyces argillaceus (pLNBIV) was generated by means ofintroducing plasmid pLNBIV in Streptomyces argillaceus ATCC 12956. Theintroduction of the plasmid was carried out by means of protoplasttransformation, following standard procedures (Kieser et al., PracticalStreptomyces genetics, The John Innes Foundation, Norwich, GreatBritain, 2000). Plasmid pLNBIV has been previously described, andcontains a series of genes encoding the biosynthesis of nucleosidyldiphosphate (NDP)-L-digitoxose (Chem. Biol. 2002, 9, 721-729; J. Nat.Prod. 2002, 65, 1685-1689). The strain Streptomyces argillaceus (pLNBIV)was deposited on 15 Nov. 2006 in the Colección Española de Cultivos Tipo(CECT) [Spanish Type Culture Collection], Universidad de Valencia,Campus de Burjassot, 46100 Burjassot (Valencia, Spain) with accessionnumber CECT 3384.

Example 2 Production of demycarosyl-3D-β-D-digitoxosyl-MTM (formulaVIII), deoliosyl-3C-α-L-digitoxosyl-MTM (formula IX),deoliosyl-3C-β-D-mycarosyl-MTM (formula X), and 3A-deolivosyl-MTM(formula XI)

For the purification of the derivatives of MTM, the strain S.argillaceus (pLNBIV) was cultured in R5A medium using a two-step culturemethod, as has been previously described (J. Bacteriol. 1998, 180,4929-4937). In the production step, eight 2 L Erlenmeyer flasks wereused, each of them containing 400 ml of medium, which were incubated for5 days. The cultures were centrifuged and filtered, and the broth wasextracted in solid phase as has been described (Chem. Biol. 2002, 9,519-531). The obtained fractions were analyzed by HPLC-MS usingchromatographic equipment coupled to a ZQ4000 mass spectrometer(Waters—Micromass), using as solvents acetonitrile and 0.1%trifluoroacetic acid (TFA) in water, and a reversed-phase column(Symmetry C18, 2.1×150 mm, Waters). The samples were eluted with 10%acetonitrile for the first 4 minutes, followed by a 10-88% acetonitrilelinear gradient for 26 minutes, at a flow of 0.25 ml/min. Detection andspectral characterization of the peaks was carried out with a photodiodedetector and Empower software (Waters). The MS analyses were carried outby means of positive-mode electrospray ionization, with a capillaryvoltage of 3 kV and cone voltages of 20 and 100 V. Those fractionscontaining derivatives of MTM (which eluted between 45 and 55 minutes)were pooled and dried under vacuum. This extract was redissolved andchromatographed in a μBondapak C18 radial compression column (PrepPakCartridge, 25×100 mm, Waters). An isocratic elution with a mixture ofacetonitrile and 0.1% TFA in water (42:58) at 10 ml/min was used.Demycarosyl-3D-β-D-digitoxosyl-MTM and 3A-deolivosyl-MTM were repurifiedin a semipreparative column (Symmetry C18, 7.8×300 mm, Waters) withisocratic elution with acetonitrile and 0.1% TFA in water (37:63), at 3ml/min. Deoliosyl-3C-α-L-digitoxosyl-MTM anddeoliosyl-3C-β-D-mycarosyl-MTM were also repurified using the samecolumn and the same solvents, but changing the mixture to 45:55. In allcases, after each purification step, the collected compounds werediluted 4 times with water and desalted and concentrated by means ofsolid-phase extraction, in order to be finally lyophilized. Thus, 14.3mg of demycarosyl-3D-β-D-digitoxosyl-MTM (formula VIII), 5.8 mg ofdeoliosyl-3C-α-L-digitoxosyl-MTM (formula IX), 3.3 mg ofdeoliosyl-3C-β-D-mycarosyl-MTM (formula X), and 10.9 mg of3A-deolivosyl-MTM (formula XI) were obtained.

The products were characterized by means of NMR spectroscopy and massspectrometry. The electrospray ionization mass spectra (ESI-MS) wereacquired using a Thermo Finnigan LCQ mass spectrometer, with sampleintroduction by direct diffusion. The high-resolution positive-mode fastatom bombardment (FAB) mass spectrometry was acquired using a VG70SQmodel mass spectrometer (with double-focusing magnetic sector). Thepseudomolecular ion MS-MS spectrometry was performed in both +ve and −vemodes to study the fragmentation pattern of the molecule. The UV spectrawere obtained with a Varian CARY 50 spectrometer, and the IR spectrawere obtained from KBr discs in a Nicolet Magna IR-560 spectrometer. Allthe NMR data were obtained in pyridine d5, using a 400 MHz Varian Inovainstrument, except the ¹³C broadband spectra, which were obtained at50.3 and 75.4 MHz in 200 and 300 MHz Varian Inova spectrometers,respectively. The δ values were adjusted with reference to the solventpeaks (δ 8.74 ppm and δ 150.35 ppm for ¹H and ¹³C NMR, respectively).All the NMR assignments are based on ¹H and ¹³C spectra using ¹H,¹³C-HSQC and CIGAR-HMBC spectra, ¹H, ¹H-DQ-COSY and NOESY spectra, whichallowed the unambiguous assignment of all NMR signals.Demycarosyl-3D-β-D-digitoxosyl-MTM (formula VIII) was furthermorestudied by means of 1D-TOCSY spectra to separately identify the spinpatterns of the sugars. The chemical structure of the compounds is shownin FIG. 4.

NMR and MS analysis of demycarosyl-3D-β-D-digitoxosyl-MTM (formulaVIII), C₅₁H₇₄O₂₄. Negative ESI-MS m/z (relative intensity): 1069 (100)[M−H], 1105/1107 (22) [M+Cl⁻], 939 (7) [M−H-Sugar 1A]. Positive ESI-MSm/z (relative intensity): 1093 (100) [M+Na], 1109 (11) [M+K], 833 (7)[M+H-{Sugar 1A and 1B}+Na], 811 (16) [M+H-Sugar 1A and 1B], 681 (14)[M+H-Trisaccharide], 421 (18) [M+H-Tri- and disaccharide]. HR-FAB m/z[M+Na⁺]: calculated, 1093.4467; obtained, 1093.4447. UV/Vis (Methanol)λmax (s): 412 (1532), 317 (1663), 279 (5112), 229 (5042) nm. IR (KBr) θ:3420 (OH), 2920 (CH), 2848 (CH), 1716 (C═O), 1631 (C═O), 1514 (C═C),1382, 1130, 1064 cm⁻¹. Table 1 shows the ¹H-NMR and ¹³C-NMR data.

NMR and MS analysis of deoliosyl-3C-α-L-digitoxosyl-MTM (formula IX),C₅₂H₇₆O₂₄. Negative ESI-MS m/z (relative intensity): 1083 (100) [M−H],1119/1121 (26) [M+Cl⁻]. Positive ESI-MS m/z (relative intensity): 1107(100) [M+Na⁺], 1123 (13) [M+K⁺], 847 (5) [M+H-{Disaccharide}+Na], 825(27) [M+H-Disaccharide], 681 (11) [M+H-Trisaccharide], 551 (34)[M+H-Sugars 1A, 1B, 1D and 1E] and 421 (22) [M+H-Tri- and disaccharide].HR-FAB m/z [M+Na⁺]: calculated, 1107.4603; obtained, 1107.4624. UV/Vis(Methanol) λmax (s): 412 (2148), 317 (2491), 278 (6851), 230 (6420) nm.IR (KBr) v: 3409 (OH), 2924 (CH), 2850 (CH), 1716 (C═O), 1634 (C═O),1514 (C═C), 1374, 1126, 1064 cm⁻¹. Table 2 shows the ¹H-NMR and ¹³C-NMRdata.

NMR and MS analysis of deoliosyl-3C-β-D-mycarosyl-MTM (formula X),C₄₆H₆₆O₂₁. Negative ESI-MS m/z (relative intensity): 953 (100) [M−H].Positive ESI-MS m/z (relative intensity): 977 (100) [M+Na⁺], 993 (5)[M+K⁺], 695 (8) [M-Sugar 1A and 1B], 681 (10) [M-Sugar 1C and 1D] and421 (20) [M+H-bis-disaccharide]. HR-FAB m/z [M+Na⁺]: calculated,977.3745; obtained, 977.3948. UV/Vis (Methanol) λmax (ε): 412 (1357),316 (1629), 278 (3274), 230 (2982) nm. IR (KBr) θ: 3425 (OH), 2924 (CH),2850 (CH), 1716 (C═O), 1631 (C═O), 1514 (C═C), 1374, 1122, 1064 cm⁻¹.Table 3 shows the ¹H-NMR and ¹³C-NMR data.

NMR and MS analysis of 3A-deolivosyl-MTM (formula XI), C₄₆H₆₆O₂₁.Negative ESI-MS m/z (relative intensity): 953 (100) [M−H], 989/991 (9)[M+Cl⁻], 823 (5) [M-Sugar 1B], 809 (8) [M+H-Sugar 1D]. Positive ESI-MSm/z (relative intensity): 955 (100) [M+Na⁺], 993 (10) [M+K⁺], 833 (13)[M+H-{Sugar 1D}+Na⁺], 825 (11) [M+H-Sugar 1B], 695 (5) [M+H-Sugar 1A and1B], 681 (25) [M+H-Sugar 1C and 1D], 551 (50) [M+H-Sugars 1A, 1B and 1D]and 421 (33) [M+H-Tri- and monosaccharide]. HR-FAB m/z [M+Na⁺]:calculated, 977.3735; obtained, 977.3950. UV/Vis (Methanol) λmax (ε):412(2178), 316 (2310), 278 (8099), 231 (7363) nm. IR (KBr) θ: 3421 (OH),2924 (CH), 2850 (CH), 1716 (C═O), 1634 (C═O), 1514 (C═C), 1374, 1122,1060 cm⁻¹. Table 4 shows the ¹H-NMR and ¹³C-NMR data.

Example 3 Obtaining the Streptomyces argillaceus (pFL845) BacterialStrain

The strain Streptomyces argillaceus (pFL845) was generated by means ofintroducing plasmid pFL845 in Streptomyces argillaceus. The introductionof the plasmid was carried out by means of protoplast transformation,following standard procedures (Kieser et al., Practical Streptomycesgenetics, The John Innes Foundation, Norwich, Great Britain, 2000).Plasmid pFL845 has been previously described, and contains a series ofgenes encoding the biosynthesis of nucleosidyl diphosphate(NDP)-D-amicetose (Chem. Commun. (Camb). 2005 Mar. 28; (12):1604-6). Thestrain Streptomyces argillaceus (pFL845) was deposited on 15 Nov. 2006in the Colección Española de Cultivos Tipo (CECT) [Spanish Type CultureCollection], Universidad de Valencia, Campus de Burjassot, 46100Burjassot (Valencia, Spain) with accession number CECT 3383.

Example 4 Production of demycarosyl-MTM (formula XII) and6-dediolivosyl-6-β-D-amicetosyl-MTM (formula XIII)

To purify the novel derivatives of mithramycin produced by S.argillaceus (pFL845), this strain was cultured in eight 2 L flaskscontaining 400 ml of R5A medium supplemented with thiostrepton (5 μg/mlf.c.). After 6 days of incubation at 30° C., the cultures werecentrifuged, filtered and a solid-phase extraction was carried out. Theextract was then subjected to a first chromatography using a μBondapakC18 cartridge. The elution was carried out at 10 ml/min using a mixtureof acetonitrile and TFA in water (42:58) as a mobile phase. A secondchromatography was then carried out in Symmetry C18 (7.8×300), at 3ml/min using a mixture of acetonitrile and TFA in water (37:63, for845-1 P1; 42:58, for 845-1 P3) as a mobile phase. The following yieldwas obtained: 16.1 mg of demycarosyl-MTM (formula XII) and 4.3 mg of6-dediolivosyl-6-β-D-amicetosyl-MTM (formula XIII). The products werecharacterized by HPLC-MS, as described in Example 2.

NMR and MS analysis of demycarosyl-MTM (formula XII), C₄₅H₆₄O₂₁.Amorphous yellow solid. [α]²⁵ _(D) −25 (c 0.032, MeOH); Negative ESI-MSm/z (relative intensity): 939 (100) [M−H], 975/977 (28) [M+Cl⁻], 809(10) [M−H-{sugar A}], 679 (5) [M−H-{Disaccharide}]. Positive ESI-MS m/z(relative intensity): 963 (100) [M+Na⁺], 979 (10) [M+K⁺], 833 (9)[M+H-{Sugar A}+Na⁺], 811 (5) [M+H-sugar A], 681 (20)[M+H-{disaccharide}], 703 (8) [M+H-{Disaccharide}+Na], 421 (15)[M+H-{bis-disaccharide}]. HR-FAB m/z [M+Na⁺]: calculated, 963.3804;obtained, 963.3793. UV/Vis (Methanol) λmax (ε): 430 (10,200), 316(6400),281 (50,400), 231 (11,000) nm. IR (KBr) θ: 3421 (OH), 2924 (CH), 2850(CH), 1716 (C═O), 1631 (C═O), 1514 (C═C), 1374, 1122, 1064 cm⁻¹. Table 5shows the ¹H-NMR and ¹³C-NMR data.

NMR and MS analysis of 6-dediolivosyl-6-β-D-amicetosyl-MTM (formulaXIII), C₄₆H₆₆O₂₀. Amorphous yellow solid. [α]²⁵ _(D) −22 (c 0.027,MeOH); Negative ESI-MS m/z (relative intensity): 937 (100) [M−H],973/975 (23) [M+Cl⁻], 823 (10) [M−H-{sugar A}]. Positive ESI-MS m/z(relative intensity): 961 (100) [M+Na⁺], 977 (15) [M+K⁺], 825 (10)[M+H-{sugar A}], 535 (9) [M+H-{Trisaccharide}], 421 (12) [M+H-{Tri- andmonosaccharide}]. HR-FAB m/z [M+Na⁺]: calculated, 961.4053; obtained,961.4045. UV/Vis (Methanol) λmax (s):430 (10,500), 316 (6,500), 281(48,400), 230 (12,600). IR (KBr) θ: 3425 (OH), 2928 (CH), 2850 (CH),1716 (C═O), 1631 (C═O), 1514 (C═C), 1374, 1122, 1064 cm⁻¹. Table 6 showsthe ¹H-NMR and ¹³C-NMR data.

Example 5 Obtaining the Streptomyces argillaceus (pFL942) BacterialStrain

The strain Streptomyces argillaceus (pFL942) was generated by means ofintroducing plasmid pFL942 in Streptomyces argillaceus. The introductionof the plasmid was carried out by means of protoplast transformation,following standard procedures (Kieser et al., Practical Streptomycesgenetics, The John Innes Foundation, Norwich, Great Britain, 2000).Plasmid pFL942 has been previously described, and contains a series ofgenes encoding the biosynthesis of nucleosidyl diphosphate(NDP)-L-mycarose (Chemistry & Biology. 2004, (11):1709-18). The strainStreptomyces argillaceus (pFL942) was deposited on May 2, 2008 in theColección Española de Cultivos Tipo (CECT) [Spanish Type CultureCollection], Universidad de Valencia, Campus de Burjassot, 46100Burjassot (Valencia, Spain) with accession number CECT 7368.

Example 6 Production of deoliosyl-demycarosyl-3C-β-D-boivinosyl-MTM(formula XVII) and demycarosyl-3D-β-D-digitoxosyl-MTM (formula VIII)

To purify the novel derivatives of mithramycin produced by S.argillaceus (pFL942), this strain was cultured in R5A solid medium. 100Agar plates were uniformly inoculated with spores and after 6 days ofincubation at 28° C., the cultures were extracted 3 times with ethylacetate. The extract was then subjected to a first chromatography usinga μBondapak C18 radial compression cartridge. The elution was carriedout at 10 ml/min using a mixture of acetonitrile and TFA in water(50:50) as a mobile phase. A second chromatography was then carried outin a Sunfire PrepC18 column (10×250 mm, Waters), at 7 ml/min using amixture of acetonitrile and 0.1% TFA in water (37:63) as a mobile phase.The HPLC fractions were collected on 0.1M potassium phosphate buffer(pH=7) and after each purification, the samples were diluted 4 timeswith water, desalted, concentrated and lyophilized. The following yieldwas obtained: 3 mg of deoliosyl-demycarosyl-3C-β-D-boivinosyl-MTM(formula XVII) and 6.9 mg of demycarosyl-3D-β-D-digitoxosyl-MTM (formulaVIII). The products were characterized by HPLC-MS, as described inExample 2. The compound demycarosyl-3D-β-D-digitoxosyl-MTM (formulaVIII) is characterized in Example 2.

NMR and MS analysis of deoliosyl-demycarosyl-3C-β-D-boivinosyl-MTM(formula XVII), C₄₅H₆₄O₂₁. Amorphous yellow solid. [α]²⁵ _(D) −22 (c0.029, MeOH); Negative ESI-MS m/z (relative intensity): 939 (100) [M−H].Positive ESI-MS m/z (relative intensity): 963 (100) [M+Na⁺], 979 (10)[M+K⁺], 833 (10) [M+Na⁺-{Sugar A}], 703 (50) [M+H-{disaccharide}], 443(12) [aglycon+Na⁺]. HR-FAB m/z [M+Na⁺]: calculated, 939.3849; obtained,939.3867. UV/Vis (Methanol) λmax (s):430 (10,600), 317 (6800), 281(49,500), 230 (10,000) nm. IR (KBr) θ: 3431 (OH), 2926 (CH), 2851 (CH),1716 (C═O), 1631 (C═O), 1514 (C═C), 1374, 1121, 1064 cm⁻¹. Table 7 showsthe ¹H-NMR and ¹³C-NMR data.

Example 7 Obtaining the Bacterial Strain Streptomyces argillaceus M7U1(pFL845)

The strain Streptomyces argillaceus M7U1 (pFL845) was generated by meansof introducing plasmid pFL845 in Streptomyces argillaceus M7U1. Theintroduction of the plasmid was carried out by means of protoplasttransformation, following standard procedures (Kieser et al., PracticalStreptomyces genetics, The John Innes Foundation, Norwich, GreatBritain, 2000). The strain Streptomyces argillaceus M7U1 has beenpreviously described (Mol. Gene. Genet. 2001, 264, 827-835). PlasmidpFL845 has been previously described, and contains a series of genesencoding the biosynthesis of nucleosidyl diphosphate (NDP)-D-D-amicetose(Chem. Commun. (Camb). 2005 Mar. 28; (12):1604-6). The strainStreptomyces argillaceus M7U1 (pFL845) was deposited on May 2, 2008 inthe Colección Española de Cultivos Tipo (CECT) [Spanish Type CultureCollection], Universidad de Valencia, Campus de Burjassot, 46100Burjassot (Valencia, Spain) with accession number CECT 7369.

Example 8 Production of6-dediolivosyl-6-β-D-amicetosyl-deoliosyl-demycarosyl-3C-β-D-boivinosyl-MTM(formula XVIII);deoliosyl-demycarosyl-3C-β-D-olivosyl-3D-β-D-digitoxosyl-MTM (formulaXIX);6-dediolivosyl-6-β-D-amicetosyl-deoliosyl-demycarosyl-3C-β-D-olivosyl-3D-β-D-digitoxosyl-MTM(formula XX) and6-dediolivosyl-6-β-D-amicetosyl-deoliosyl-3C-β-D-olivosyl-MTM (formulaXXI)

To purify the novel derivatives of mithramycin produced by S.argillaceus M7U1 (pFL845), this strain was cultured in R5A solid medium.100 Agar plates were uniformly inoculated with spores and after 6 daysof incubation at 28° C., the cultures were extracted 3 times with ethylacetate. The extract was then subjected to a first chromatography usinga μBondapak C18 radial compression cartridge. The elution was carriedout at 10 ml/min using a mixture of acetonitrile and TFA in water(50:50) as a mobile phase. A second chromatography was then carried outin a Sunfire PrepC18 column (10×250 mm, Waters), at 7 ml/min using amixture of acetonitrile and 0.1% TFA in water (40:60) as a mobile phase.The HPLC fractions were collected on 0.1M potassium phosphate buffer(pH=7) and after each purification, the samples were diluted 4 timeswith water, desalted, concentrated and lyophilized. The following yieldwas obtained: 1.7 mg of6-dediolivosyl-6-β-D-amicetosyl-deoliosyl-demycarosyl-3C-β-D-boivinosyl-MTM(formula XVIII), 6.7 mg ofdeoliosyl-demycarosyl-3C-β-D-olivosyl-3D-β-D-digitoxosyl-MTM (formulaXIX), 12.2 mg of6-dediolivosyl-6-β-D-amicetosyl-deoliosyl-demycarosyl-3C-β-D-olivosyl-3D-β-D-digitoxosyl-MTM(formula XX) and 17 mg of6-dediolivosyl-6-β-D-amicetosyl-deoliosyl-3C-8-D-olivosyl-MTM (formulaXXI). The products were characterized by HPLC-MS, as described inExample 2.

NMR and MS analysis of6-dediolivosyl-6-β-D-amicetosyl-deoliosyl-demycarosyl-3C-β-D-boivinosyl-MTM(formula XVIII): C₃₉H₅₄O₁₇. Amorphous yellow solid. [α]²⁵ _(D) −23 (c0.026, MeOH); Negative ESI-MS m/z (relative intensity): 793 (10%) [M−H],777 (100%) (M−H2O). Positive ESI-MS m/z (relative intensity): 795 (25)[M+H], 817 (20) [M+Na⁺], 687 (100), [M+H-{sugar A}], 673 (11) [M+H{sugarA and 1C}], 443 (12) [aglycon+Na]. HR-FAB m/z [M+Na⁺]: calculated,817.3253; obtained, 817.3238. UV/Vis (Methanol) λmax (ε): 430 (10,800),316 (6700), 280 (50,700), 231 (13,000) nm. IR (KBr) θ: 3428 (OH), 2925(CH), 2850 (CH), 1716 (C═O), 1632 (C═O), 1514 (C═C), 1374, 1121, 1063cm⁻¹. Table 8 shows the ¹H-NMR and ¹³C-NMR data.

NMR and MS analysis ofdeoliosyl-demycarosyl-3C-β-D-olivosyl-3D-β-D-digitoxosyl-MTM (formulaXIX), C₅₁H₇₄O₂₄. Amorphous yellow solid. [α]²⁵ _(D) −21 (c 0.020, MeOH);Negative ESI-MS m/z (relative intensity): 1069 (20) [M−H]. PositiveESI-MS m/z (relative intensity): 1071 (48) [M+H], 1093 (26) [M+Na⁺], 963(28) [M+Na⁺-{monosaccharide}], 833 (16)) [M+Na⁺-{disaccharide}], 703(12) [M+Na⁺-{Trisaccharide}], 550 (14) [M+Na⁺-{tetrasaccharide], 443(26) [M+H-{Tri- and disaccharide}]. HR-FAB m/z [M+Na⁺]: calculated,1093.4462; obtained, 1093.4447. UV/Vis (Methanol) λmax (ε): 430(10,600), 316 (6500), 280 (49,500), 231 (12,800) nm. IR (KBr) θ: 3423(OH), 2921 (CH), 2850 (CH), 1716 (C═O), 1631 (C═O), 1514 (C═C), 1382,1131, 1064 cm⁻. Table 9 shows the ¹H-NMR and ¹³C-NMR data.

NMR and MS analysis of6-dediolivosyl-6-β-D-amicetosyl-deoliosyl-demycarosyl-3C-β-D-olivosyl-3D-β-D-digitoxosyl-MTM(formula XX), C₄₅H₆₂O₂₀. Amorphous yellow solid. [α]²⁵ _(D) −15 (c0.024, MeOH); Positive ESI-MS m/z (relative intensity): 947 (25)[M+Na⁺], 817 (100) [M+Na⁺-{sugar C}], 795 (12) [M+H-sugar C]. HR-FAB m/z[M+Na⁺]: calculated, 947.3883; obtained, 947.3867. UV/Vis (Methanol)λmax (ε): 430 (10,400), 316 (6500), 281 (48,000), 232 (11,900) nm. IR(KBr) θ: 3426 (OH), 2928 (CH), 2843 (CH), 1716 (C═O), 1632 (C═O), 1514(C═C), 1374, 1121, 1063 cm⁻. Table 10 shows the ¹H-NMR and ¹³C-NMR data.

NMR and MS analysis of6-dediolivosyl-6-β-D-amicetosyl-deoliosyl-3C-β-D-olivosyl-MTM (formulaXXI), C₄₅H₆₄O₂₁. Negative ESI-MS m/z (relative intensity): XXX. PositiveESI-MS m/z (relative intensity): XXX. HR-FAB m/z [M+Na⁺]: calculated,940.39; obtained, XXX. UV/Vis (Methanol) λmax (ε): XXX. IR (KBr) θ: XXX.Table 11 shows the ¹H-NMR and ¹³C-NMR data.

Example 9 Antitumor activity of demycarosyl-3D-β-D-digitoxosyl-MTM(formula VIII), deoliosyl-3C-α-L-digitoxosyl-MTM (formula IX),deoliosyl-3C-β-D-mycarosyl-MTM (formula X), 3A-deolivosyl-MTM (formulaXI), demycarosyl-MTM (formula XII), 6-dediolivosyl-6-β-D-amicetosyl-MTM(formula XIII)

deoliosyl-demycarosyl-3C-β-D-boivinosyl-MTM [formula (XVII)];6-dediolivosyl-6-β-D-amicetosyl-deoliosyl-demycarosyl-3C-β-D-boivinosyl-MTM[formula (XVIII)];deoliosyl-demycarosyl-3C-β-D-olivosyl-3D-β-D-digitoxosyl-MTM [formula(XIX)];6-dediolivosyl-6-β-D-amicetosyl-deoliosyl-demycarosyl-3C-β-D-olivosyl-3D-β-D-digitoxosyl-MTM[formula (XX)], and6-dediolivosyl-6-β-D-amicetosyl-deoliosyl-3C-β-D-olivosyl-MTM [formula(XXI)].

The derivatives of MTM were assayed against a series of cell lines fromtumors. Cell growth and viability were quantitatively determined, usinga colorimetric type assay, using the reaction with sulforhodamine B(SRB) according to the technique described by Faircloth et al. (Journalof Tissue and Culture Methods 1988, 11, 201-205). The results are shownin Table 5.

96-well microtiter plates were inoculated with cells (5×10³ cells perwell) in aliquots of 195 μl of medium, incubating them for 18 hours inmedium without added compound, to allow the cells to adhere to thesurface. The compounds to be assayed were then added, in 5 μl samples,in a concentration range from 10 to 10⁻⁸ μg/ml, dissolved in DMSO/EtOH(0.2% in PS buffer). After 48 hours of exposure, the antitumor effectwas measured using the SRB technique: the cells were fixed adding 50 μlof 50% (w/v) cold trichloroacetic acid and incubated for 60 minutes at4° C. The plates were washed with deionized water and dried. 100 μl ofSRB solution (0.4% w/v in 1% acetic acid) were added to each well, andincubated for 10 minutes at room temperature. The non-bound SRB waseliminated, washing with 1% acetic acid. The plates were air dried andthe bound dye was dissolved with Tris buffer. Optical densities wereread in an automatic plate spectrophotometer reader at a wavelength of490 nm. Table 12 shows the results of GI₅₀ (growth inhibition). The sixcompounds assayed showed cytotoxic activity against the tumor cell linesassayed, demycarosyl-3D-β-D-digitoxosyl-MTM (formula VIII) being themost active (with an activity similar to that of MTM), anddemycarosyl-MTM (formula XII) and 6-dediolivosyl-6-β-D-amicetosyl-MTM(formula XIII) being the least active.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1. Chemical structure of mithramycin.

FIG. 2. Mithramycin biosynthesis. Abbreviations: AcO, acetate; MalO,malonate; Mtm PKS, mithramycin polyketide synthase; preMTMone,premithramycinone; preMTM-A3, premithramycin A3; preMTM-B,premithramycin B; MTM, mithramycin.

FIG. 3A. HPLC analysis of a Streptomyces argillaceus (pFL845) extract.Peak identifier: 1=mithramycin (MTM); 2=premithramycin A1 (preMTM);3=demycarosyl-MTM [formula (XII)]; 4=6-dediolivosyl-6-β-D-amicetosyl-MTM[formula (XIII)];

FIG. 3B. HPLC analysis of a Streptomyces argillaceus (pLNBIV) extract.Peak identifier: 1=mithramycin (MTM); 2=premithramycin A1 (preMTM);3=demycarosyl-MTM [formula (XII)], 3A-deolivosyl-MTM (XI), anddemycarosyl-3D-β-D-digitoxosyl-MTM [formula (VIII)];4=deoliosyl-3C-α-L-digitoxosyl-MTM [formula (IX)];5=deoliosyl-3C-β-D-mycarosyl-MTM [formula (X)].

FIG. 3C. HPLC Analysis of a Streptomyces argillaceus (pFL942) extract.Peak identifier: 1=mithramycin (MTM);2=demycarosyl-3D-β-D-digitoxosyl-MTM [formula (VIII)];3=deoliosyl-demycarosyl-3C-β-D-boivinosyl-MTM [formula (XVII)];

FIG. 3D. HPLC analysis of a Streptomyces argillaceus M7U1 (pFL845)extract. Peak identifier: 1=premithramycin A1 (preMTM);2=6-dediolivosyl-6-β-D-amicetosyl-deoliosyl-demycarosyl-3C-β-D-boivinosyl-MTM[formula (XVIII)];3=deoliosyl-demycarosyl-3C-β-D-olivosyl-3D-β-D-digitoxosyl-MTM [formula(XIX)];4=6-dediolivosyl-6-β-D-amicetosyl-deoliosyl-demycarosyl-3C-β-D-olivosyl-3D-β-D-digitoxosyl-MTM[formula (XX)];5=6-dediolivosyl-6-β-D-amicetosyl-deoliosyl-3C-β-D-olivosyl-MTM [formula(XXI)].

FIG. 4 a. Chemical structures of demycarosyl-3D-β-D-digitoxosyl-MTM(formula VIII), deoliosyl-3C-α-L-digitoxosyl-MTM [formula (IX)],deoliosyl-3C-β-D-mycarosyl-MTM [formula (X)], 3A-deolivosyl-MTM [formula(XI)], demycarosyl-MTM [formula (XII)], and6-dediolivosyl-6-β-D-amicetosyl-MTM [formula (XIII)].

FIG. 4 b. Chemical structures ofdeoliosyl-demycarosyl-3C-β-D-boivinosyl-MTM [formula (XVII)];6-dediolivosyl-6-β-D-amicetosyl-deoliosyl-demycarosyl-3C-β-D-boivinosyl-MTM[formula (XVIII)];deoliosyl-demycarosyl-3C-β-D-olivosyl-3D-β-D-digitoxosyl-MTM [formula(XIX)];6-dediolivosyl-6-β-D-amicetosyl-deoliosyl-demycarosyl-3C-β-D-olivosyl-3D-β-D-digitoxosyl-MTM[formula (XX)], and6-dediolivosyl-6-β-D-amicetosyl-deoliosyl-3C-β-D-olivosyl-MTM [formula(XXI)].

TABLE 1 ¹H- and ¹³C-NMR data of demycarosyl-3D-β-D-digitoxosyl-MTM[formula (VIII)] (Pyridine-d₅, 400 MHz). C ¹H-NMR δ (J in Hz) ¹³C-NMR(δ) Multiplicity HMBC NOESY 1   — 204.3 C 2   4.96 (d, J = 11.6 Hz) 78.7CH C-1, C-1(A*), C-3, C-4, C-1′ H-1(C*), H-3, H-4α, H-4e 3   3.48 (m)42.8 C C-2, C-4, C-1′ H-2, H-4a, H-4e, H-1′ 4a  3.11 (dd, J = 15.9 and3.6 Hz) 28.5 CH₂ C-2, C-3, C-1′ H-3, H-2 4e  3.27 (dd, J = 15.9 and 13.0Hz) H-3, H-2 4a  — 137.2 C 5   7.05 (s) 102.2 CH C-6, C-8a, C-7, C-106   — 160.4 C H-10, H-1(A*), H-5(A*) 7   — 111.7 C   7-CH₃ 2.47 (s) 9.4CH₃ C-6, C-7, C-8 8   — 156.9 C 8a  — 109.4 C 9   — 165.7 C 9a  — 108.9C 10   6.63 (s) 117.4 CH C-5, C-5a, C-8a, C-9a H-5, H-1(A*), H-4a, H-4e10a  — 139.5 C 1′  5.49 (d, J = 1.2 Hz) 83.1 CH C-2, C-3, C-4, C-1′-Me,C-2′ H-2, H-3, H-1′(Me)    1′-CH₃ 3.69 (s) 59.1 C-1′, C-2′, C-3 2′  —213.5 C 3′  4.70 (d, J = 2.8 Hz) 81.4 CH C-2′, C-4′, C-5′ H-4′, H-5′ 4′ 4.84 (dq, J = 6.2 and 2.8 Hz) 69.6 CH C-2′, C-3′, C-5′ H-5′, H-3′ 5′ 1.60 (d, J = 6.2 Hz) 19.7 CH₃ C-3′, C-4′ H-4′-H-3′ 1A 5.68 (dd, J = 9.6and 2.0 Hz) 97.9 CH C-6 H-3(A*), H-5(A*), H-2a(A*), H-2e(A*), H-5, H-10 2αA 2.25 (ddd, J = 12, 12 and 9.6 Hz) 38.0 CH₂ C-1(A*), C-3(A*),C-4(A*) H-1(A*), H-4((A*)  2eA 2.72 (ddd, J = 12, 5.0 and 2.0 Hz)H-1(A*), H-3(A*), H-2α(A*) 3A 4.29 (ddd, J = 12, 9.0 and 5.0 Hz) 80.1CH₂ C-1(B*), C-4(A*) H-1(A*), H-1(B*)H-5(A*), H-2α(A*), H-2e(A*) 4A 3.63(t, J = 9.0 Hz) 76.1 CH C-3(A*), C-5(A*), C-6(A*) H-2α(A*), H₃-6(A*) 5A4.00 (dq, J = 9.0 and 6.0 Hz) 73.9 CH C-1(A*), C-3(A*), C-4(A*),H-1(A*), H-3(A*), C-6(A*) H₃-6(A*) 6A 1.71 (d, J = 6.0 Hz) 19.4 CH₃C-4(A*), C-5(A*) H-4(A*), H-5(A*) 1B 5.05 (dd, J = 9.6 and 2.0 Hz) 99.4CH C-3(A*), H-2α(B*), 2e(B*)H-3(A*), H-3(B*), H-5(B*)  2αB 2.15 (ddd, J= 12, 12 and 9.6 Hz) 41.6 CH₂ C-1(B*), C-3(B*), C-4(B*) H-1(B*), H-4(B*) 2eB 2.65 (ddd, J = 12, 5.0 and 2.0 Hz) H-1(B*) 3B 4.16 (ddd, J = 12,9.0 and 5.0 Hz) 72.4 CH C-4(B*) H-2a(B*), H-2e(B*), H-1(B*), H-5(B*) 4B3.58 (t, J = 9.0 Hz) 78.7 CH C-3(B*), C-5(B*), C-6(B*) H-2α(B*),H₃-6(B*) 5B 3.75 (dq, J = 9.0 and 6.0 Hz) 74.6 CH C-1(B*), C-3(B*),C-4(B*), H-1(B*), H-3(B*), C-6(B*) H₃-6 (B*) 6B 1.64 (d, J = 6.0 Hz)19.1 CH₃ C-4(B*), C-5(B*) H-5(B*) 1C 5.39 (dd, J = 9.6 and 2.0 Hz) 101.9CH C-2 H-2, H-3(C*), H-5(C*), H-2e(C*)  2αC 2.02 (ddd, J = 12, 12 and9.6 Hz) 38.7 CH₂ C-1(C*), C-3(C*), C-4(C*) H-4(C*)  2eC 2.99 (ddd, J =12, 5.0 and 2.0 Hz) H-1(C*) 3C 4.06 (ddd, J = 12, 9.0 and 5.0 Hz) 81.7CH C-1(D*), C-4(C*) H-1(C*), H-1(D*), H-5(C*), H-2e(C*) 4C 3.46 (t, J =9.0 Hz) 76.3 CH C-3(C*), C-5(C*), C-6(C*) H-2α(C*), H₃-6(C*) 5C 3.68(dq, J = 9.0 and 6.0 Hz) 73.5 CH C-4(C*), C-6(C*) H-3(C*), H-1(C*),H₃-6(C*) 6C 1.59 (d, J = 6.0 Hz) 19.7 CH₃ C-4(C*), C-5(C*) H-5(C*),H-4(C*) 1D 4.78 (dd, J = 9.6 and 2.0 Hz) 100.4 CH C-3(C*) H-3(D*),H-5(D*), H-2e(D*), H-3(C*)  2αD 2.42 (ddd, J = 12, 12 and 9.6 Hz) 33.3CH₂ C-1(D*), C-3(D*), C-4(D*) H-1(D*)  2eD 2.18 (ddd, J = 12, 5.0 and2.0 Hz) 3D 4.22 (ddd, J = 12, 5.0 and 2.5 Hz) 77.2 CH C-1(E*), C-4(D*)H-1(D*), H-2e(D*), H-5(D*), H-1(E*) 4D 4.10 (brd, J = 2.5 Hz) 70.2 CHC-3(D*), C-5(D*) H₃-6(D*) 5D 3.71 (dq, J = 6.0 and 2.5 Hz) 74.6 CHC-4(D*), C-6(D*) H-1(D*), H-3(D*), H₃-6(D*) 6D 1.54 (d, J = 6.0 Hz) 19.4CH₃ C-4(D*), C-5(D*) H-5(D*) 1E 5.62 (dd, J = 9.6 and 2.0 Hz) 97.8 CHC-3(D*) H-5(E*), H-2α(E*)H-2e(E*), H-3(D*)  2αE 2.00 (ddd, J = 12, 9.6and 3.0 Hz) 40.3 CH₂ C-1(E*), C-3(E*), C-4(E*) H-1(E*), H-2α(E*)   2e-E2.45 (ddd, J = 12, 3.0 and 2.0 Hz) 3E 4.45 (ddd, J = 3.0, 3.0, and 3.0Hz) 69.1 CH C-4(E*) H-4(E*) 4E 3.62 (dd, J = 9.2 and 3.0 Hz) 72.4 CHC-3(E*), C-5(E*) H-2α(E*), H-3(E*), H₃-6(E*) 5E 4.42 (dq, J = 9.2 and6.0 Hz) 71.2 CH C-1(E*), C-4(E*), H₃-6(E*), H-1(E*) C-6(E*) 6E 1.61 (d,J = 6.0 Hz) 17.9 CH₃ C-4(E*), C-5(E*) H-5(E*) *A = B = C = D = E: sugars

TABLE 2 ¹H- and ¹³C-NMR data of deoliosyl-3C-α-L-digitoxosyl-MTM[formula (IX)] (Pyridine-d₅, 400 MHz). C ¹H-NMR δ (J in Hz) ¹³C-NMR (δ)C HMBC NOESY 1   — 204.2 C 2   4.93 (d, J = 11.6 Hz) 77.9 CH C-1,C-1(A*), C-3, C-4, C-1′ H-1(C*), H-3, H-4a, H-4e 3   3.41 (m) 42.8 CC-2, C-4, C-1′ H-2, H-4a, H-4e, H-1′ 4a  3.08 (dd, J = 15.9 and 3.6 Hz)28.2 CH₂ C-2, C-3, C-1′ H-3, H-2 4e  3.26 (dd, J = 15.9 and 13.0 Hz)H-3, H-2 4a  — 137.2 C 5   7.04 (s) 102.1 CH C-6, C-8a, C-7, C-10 6   —160.4 C H-10, H-1(A*), H-5(A*) 7   — 111.6 C   7-CH₃ 2.47 (s) 9.4 CH₃C-6, C-7, C-8 8   — 157.0 C 8a  — 109.4 C 9   — 165.7 C 9a  — 108.9 C10   6.61 (s) 117.4 CH C-5, C-5a, C-8a, C-9a H-5, H-1(A*), H-4a, H-4e10a  — 139.4 C 1′  5.46 (d, J = 1.2 Hz) 83.1 CH C-2, C-3, C-4, C-1′-CH₃,C-2′ H-2, H-3, H-1′(Me)    1′-CH₃ 3.69 (s) 59.4 CH₃ C-1′, C-2′, C-3 2′ — 213.4 C 3′  4.71 (d, J = 2.8 Hz) 81.3 CH C-2′, C-4′, C-5′ H-4′, H-5′4′  4.84 (dq, J = 6.2 and 2.8 Hz) 69.6 CH C-2′, C-3′, C-5′ H-5′, H-3′5′  1.58 (d, J = 6.2 Hz) 21.1 CH₃ C-3′, C-4′ H-4′-H-3′ 1A 5.67 (dd, J =9.6 and 2.0 Hz) 97.9 CH C-6 H-5, H-10, H-3(A*), H-5(A*), H-2α(A*),H-2e(A*)  2αA 2.24 (ddd, J = 12, 12 and 9.6 Hz) 37.7 CH₂ C-1(A*),C-3(A*) H-1(A*), H-4(A*)  2eA 2.73 (ddd, J = 12, 5.0 and 2.0 Hz) H-1(A*)3A 4.29 (ddd, J = 12, 9.0 and 5.0 Hz) 80.1 CH₂ C-1(B*), C-4(A*) H-1(A*),H-1(B*), H-5(A*), H-2e(A*) 4A 3.63 (t, J = 9.0 Hz) 76.1 CH C-3(A*),C-5(A*), C-6(A*) H-2α(A*), H₃-6(A*) 5A 4.00 (dq, J = 9.0 and 6.0 Hz)73.9 CH C-4(A*), C-6(A*) H-1(A*), H-3(A*), H-4(A*), H₃-6(A*) 6A 1.71 (d,J = 6.0 Hz) 19.6 CH₃ C-4(A*), C-5(A*) H-4(A*), H-5(A*), 1B 5.05 (dd, J =9.6 and 2.0 Hz) 99.3 CH C-3(A*) H-3(A*), H-3(B*), H-5(B*), H-2α(B*),2e(B*)  2αB 2.17 (ddd, J = 12, 12 and 9.6 Hz) 41.6 CH₂ C-1(B*), C-3(B*)H-1(B*), H-4(B*)  2eB 2.65 (ddd, J = 12, 5.0 and 2.0 Hz) H-1(B*) 3B 4.15(ddd, J = 12, 9.0 and 5.0 Hz) 72.4 CH C-1(B*), C-4(B*) H-1(B*), H-4(B*),H-5(B*), 4B 3.58 (t, J = 9.0 Hz) 78.7 CH C-3(B*), H-2α(B*), H-3(B*),H-5(B*), H₃-6(B*) C-5(B*), C-6(B*) 5B 3.75 (dq, J = 9.0 and 6.2 Hz) 74.0CH C-4(B*), C-6(B*) H-1(B*), H-3(B*), H-4(B*), H₃-6(B*), 6B 1.64 (d, J =6.2 Hz) 19.3 CH₃ C-4(B*), C-5(B*) H-4(B*), H-5(B*) 1C 5.37 (dd, J = 9.6and 2.0 Hz) 101.9 CH C-2 H-2, H-3(C*), H-5(C*), H-2e(C*), H-2α(C*)  2αC1.93 (ddd, J = 12, 12 and 9.6 Hz) 37.7 CH₂ C-3(C*) H-4(C*)  2eC 2.98(ddd, J = 12, 5.0 and 2.0 Hz) H-1(C*), H-1(D*), H-3(C*), H-2α(C*) 3C4.08 (ddd, J = 12, 9.0 and 5.0 Hz) 77.9 CH C-1(D*), C-4(C*) H-1(C*),H-5(C*), H-4(C*), H-2e(C*) 4C 3.48 (t, J = 9.0 Hz) 76.5 CH C-3(C*),C-6(C*) H-2α(C*), H-5(C*), H-6(C*) 5C 3.68 (dq, J = 9.0 and 6.0 Hz) 73.4CH C-4(C*), C-6(C*) H-1(C*), H-3(C*), H-4(C*) H₃-6(C*) 6C 1.57 (d, J =6.0 Hz) 19.4 CH₃ C-4(C*), C-5(C*) H-4(C*), H-5(C*) 1D 5.22 (dd, J = 4.0and 2.3 Hz) 94.89 CH C-3(C*) H-3(D*), H-2e(C*), H-2e(D*), H-2α(D*)  2αD2.02 (ddd, J = 14.4, 4.0 and 3.0 Hz) 34.6 CH₂ C-1(D*), C-3(D*) H-1(D*),H-3(D*), H-2e(D*)  2eD 2.35(ddd, J = 14.4, 3.0 and 2.3 Hz) H-1(D*),H-3(D*), H-2α(D*) 3D 4.39 (ddd, J = 3.0, 3.0 and 3.0 Hz) 75.2 CHC-1(D*), C-4(D*), C-5(D*) H-1(D*), H-2α(D*), H-2e(D*) 4D 3.67 (dd, J =9.0 and 3.0 Hz) 72.8 CH C-5(D*), C-6(D*), C-1(E*) H-5(D*), H₃-6(D*),H-1(E*), 5D 4.69 (dq, J = 9.0 and 6.2 Hz) 67.4 CH C-4(D*), C-6(D*)H-1(D*), H-4(D*), H₃-6(D*) 6D 1.54 (d, J = 6.2 Hz) 18.9 CH₃ C-4(D*),C-5(D*) H-4(D*), H-5(D*) 1E 5.44 (dd, J = 9.6 and 2.0 Hz) 98.7 CHC-4(D*) H-2α(E*), H-2e(E*), H-4(D*), H-5(E*)  2αE 1.86 (dd, J = 13.0,and 9.0 Hz) 45.5 CH₂ C-1(E*), C-3(E*) H-1(E*), H-4(E*)  2eE 2.41 (dd, J= 13.0 and 2.0 Hz) H-1(E*) 3E — 71.4 CH 4E 3.31 (d, J = 9.2 Hz) 77.8 CHC-3(E*)Me, C-5(E*), C-6(E*) H-2α(E*), H₃-3(E*), H-5(E*), H₃-6(E*) 5E4.22 (dq, J = 9.2 and 6.0 Hz) 72.2 CH H-5(E*), H₃-6(E*) 6E 1.60 (d, J =6.0 Hz) 19.1 CH₃ C-4(E*), C-5(E*) H-4(E*), H-5(E*)   3E-Me 1.44 (s) 28.2CH₃ C-3(E*), C-4(E*), C-2(E*) H-4(E*) *A = B = C = D = E: sugars

TABLE 3 ¹H- and ¹³C-NMR data of deoliosyl-3C-β-D-mycarosyl-MTM [formula(X)] (Pyridine-d₅, 400 MHz). C ¹H-NMR δ (J in Hz) ¹³C-NMR (δ)Multiplicity HMBC NOESY 1   — 204.2 C 2   4.96 (d, J = 11.6 Hz) 77.9 CHC-1, C-1(A*), C-3, C-4, C-1′ H-1(C*), H-3, H-4a, H-4e 3   3.48 (m) 42.6C C-2, C-4, C-1′ H-2, H-4a, H-4e, H-1′ 4a  3.10 (dd, J = 15.9 and 3.6Hz) 28.2 CH₂ C-2, C-3, C-1′ H-3, H-2 4e  3.27 (dd, J = 15.9 and 13.0 Hz)H-3, H-2 4a  — 137.2 C 5   7.04 (s) 102.2 CH C-6, C-8a, C-7, C-10 6   —160.5 C H-10, H-1(A*), H-5(A*) 7   — 111.2 C   7-CH₃ 2.47 (s) 8.9 CH₃C-6, C-7, C-8 8   — 157.0 C 8a  — 109.3 C 9   — 166.0 C 9a  — 108.2 C10   6.62 (s) 117.4 CH C-5, C-5a, C-8a, C-9a H-5, H-1(A*), H-4a, H-4e10a  — 139.4 C 1′  5.49 (d, J = 1.2 Hz) 83.0 CH C-2, C-3, C-4, C-1′-CH₃,C-2′ H-2, H-3, H-1′(Me)    1′-CH₃ 3.71 (s) 59.1 C-1′, C-2′, C-3 2′  —213.2 C 3′  4.71 (d, J = 2.8 Hz) 81.0 CH C-2′, C-4′, C-5′ H-4′, H-5′ 4′ 4.84 (dq, J = 6.2 and 2.8 Hz) 69.3 CH C-2′, C-3′, C-5′ H-5′, H-3′ 5′ 1.60 (d, J = 6.2 Hz) 20.7 CH₃ C-3′, C-4′ H-4′-H-3′ 1A 5.67 (dd, J = 9.6and 2.0 Hz) 97.9 CH C-6 H-5, H-5(A*), H-3(A*), H-2e(A*), H-10  2αA 2.25(ddd, J = 12, 12 and 9.6 Hz) 37.6 CH₂ C-1(A*), C-3(A*) H-4(A*),  2eA2.72 (ddd, J = 12, 5.0 and 2.0 Hz) H-1(A*) 3A 4.28 (ddd, J = 12, 9.0 and5.0 Hz) 80.0 CH₂ C-1(B*), C-4(A*) H-1(A*), H-1(B*), H-5(A*) 4A 3.63 (t,J = 9.0 Hz) 75.9 CH C-3(A*), C-5(A*), C-6(A*) H-2α(A*), H₃-6(A*) 5A 3.99(dq, J = 9.0 and 6.0 Hz) 73.8 CH C-4(A*), C-6(A*) H-1(A*), H-3(A*),H₃-6(A*) 6A 1.71 (d, J = 6.0 Hz) 19.0 CH₃ C-5(A*), C-4(A*) H-4(A*),H-5(A*) 1B 5.05 (dd, J = 9.6 and 2.0 Hz) 99.4 CH C-3(A*) H-3(B*),H-3(A*), H-2e(B*), H-2e(B*), H-5(B*)  2αB 2.17 (ddd, J = 12, 12 and 9.6Hz) 41.2 CH₂ C-1(B*), C-3(B*) H-1(B*), H-4(B*)  2eB 2.65 (ddd, J = 12,5.0 and 2.0 Hz) H-1(B*) 3B 4.14 (ddd, J = 12, 9.0 and 5.0 Hz) 72.1 CHC-4(B*) H-3(A*), H-1(B*), H-5(B*) 4B 3.58 (t, J = 9.0 Hz) 78.5 CHC-5(B*), C-6(B*) H-2α(B*) 5B 3.75 (dq, J = 9.0 and 6.0 Hz) 73.7 CHC-4(B*), C-6(B*) H-1(B*), H-3(B*), H₃-6(B*) 6B 1.64 (d, J = 6.0 Hz) 18.9CH₃ C-4(B*), C-5(B*) H-5(B*) 1C 5.40 (dd, J = 9.6 and 2.0 Hz) 101.6 CHC-2 H-2, H-3(C*), H-5(C*), H-2e(C*)  2αC 2.02 (ddd, J = 12, 12 and 9.6Hz) 38.5 CH₂ C-3(C*) H-4(C*)  2eC 2.99 (ddd, J = 12, 5.0 and 2.0 Hz) 3C4.03 (ddd, J = 12, 9.0 and 5.0 Hz) 81.1 CH C-1(D*), C-4(C*) H-1(C*),H-1(D*), H-5(C*), H-2e(C*) 4C 3.48 (t, J = 9.0 Hz) 76.3 CH C-3(C*),C-5(C*) H-2α(C*), H₃-6(C*) 5C 3.69 (dq, J = 9.0 and 6.0 Hz) 73.6 CHC-4(C*), C-6(C*) H-3(C*), H-1(C*), H₃-6(C*) 6C 1.58 (d, J = 6.0 Hz) 18.7CH₃ C-4(C*), C-5(C*) H-4(C*), H-5(C*) 1D 5.46 (dd, J = 9.6 and 2.0 Hz)98.9 CH C-3(C*) H-3(C*), H-5(D*)  2αD 1.86 (dd, J = 13.0 and 9.6 Hz)45.2 CH₂ C-1(D*), C-3(D*), H-2e(D*)  2eD 2.33 (dd, J = 13.0 and 2.0 Hz)3D — 71.2 CH H-4(D*) 4D 3.35 (d, J = 9.2 Hz) 77.4 CH C-3(D*), C-5(D*) 5D4.29 (dq, J = 9.2 and 6.2 Hz) 72.1 CH C-4(D*), C-6(D*) H-1(D*) 6D 1.61(d, J = 6.2 Hz) 19.0 CH₃ C-4(D*), C-5(D*) H-5(D*), H-3D-Me   3D-Me 1.5027.9 CH₃ C-2(D*), C-4(D*), C-3(D*) H-4(D*) *A = B = C = D: sugars

TABLE 4 ¹H- and ¹³C-NMR data of 3A-deolivosyl-MTM [formula (XI)](Pyridine-d₅, 400 MHz). C ¹H-NMR δ (J in Hz) ¹³C-NMR (δ) C HMBC NOESY 1— 204.4 C — 2 4.96 (d, J = 11.6 Hz) 77.9 CH C-1, C-1(A*), C-3, C-4, C-1′H-1(C*), H-3, H-4a, H-4e 3 3.48 (m) 42.6 C C-2, C-4, C-1′ H-2, H-4a,H-4e, H-1′ 4a 3.12 (dd, J = 15.9 and 3.6 Hz) 28.1 CH₂ C-2, C-3, C-1′H-3, H-2 4e 3.26 (dd, J = 15.9 and 13.0 Hz) H-3, H-2 4a — 137.2 C 5 7.04(s) 102.2 CH C-6, C-8a, C-7, C-10 6 — 160.6 C H-10, H-1(A*), H-5(A*) 7 —111.7 C 7-CH₃ 2.48 (s) 8.9 CH₃ C-6, C-7, C-8 8 — 157.0 C 8a — 109.4 C 9— 165.9 C 9a — 108.9 C 10 6.62 (s) 117.4 CH C-5, C-5a, C-8a, C-9a H-5,H-1(A*), H-4a, H-4e 10a — 139.5 C 1′ 5.49 (d, J = 1.2 Hz) 83.0 CH C-2,C-3, C-4, C-1′-CH₃, C-2′ H-2, H-3, H-1′(Me) 1′-CH₃ 3.69 (s) 59.1 C-1′,C-2′, C-3 2′ — 213.5 C 3′ 4.70 (d, J = 2.8 Hz) 81.1 CH C-2′, C-4′, C-5′H-4′, H-5′ 4′ 4.84 (dq, J = 6.0 and 2.8 Hz) 69.4 CH C-2′, C-3′, C-5′H-5′, H-3′ 5′ 1.59 (d, J = 6.0 Hz) 20.7 CH₃ C-3′, C-4′ H-4′-H-3′ 1A 5.63(dd, J = 9.6 and 2.0 Hz) 98.0 CH C-6 H-5, H-3(A*), H-(5*), H-2e(A*) 2aA2.00 (ddd, J = 12.0, 12.0 and 9.6 Hz) 36.7 CH₂ C-1(A*), C-3(A*), C-4(A*)H-4(A*) 2eA 2.73 (ddd, J = 12.0, 5.0 and 2.0 Hz) H-1(A*) 3A 4.35 (ddd, J= 12, 9.2 and 5.0 Hz) 74.2 CH₂ C-2(A*), C-4(A*) H-1(A*), H-(5*) 4A 3.63(t, 9.2) 75.4 CH C-3(A*), C-5(A*), C-6(A*) H-2a(A*), H₃-6(A*) 5A 4.01(dq, J = 9.2 and 6.0 Hz) 73.8 CH C-1(A*), C-3(A*), C-4(A*), C-6(A*)H-1(A*), H-4(A*), H₃-6(A*) 6A 1.70 (d, J = 6.0 Hz) 19.4 CH₃ C-4(A*),C-5(A*) H-4(A*), H-5(A*) 1B 5.40 (dd, J = 9.6 and 2.0 Hz) 101.7 CH C-2H-2, H-5(B*), H-3(B*), H-2e(B*) 2aB 2.02 (ddd, J = 12, 12 and 9.6 Hz)38.4 CH₂ C-1(B*), C-3(B*), C-4(B*) H-4(B*) 2eB 2.99 (ddd, J = 12, 5.0and 2.0 Hz) H-1(B*) 3B 4.06 (ddd, J = 12, 9.0 and 5.0 Hz) 81.6 CHC-1(C*), C-4(B*) H-1(B*), H-5(B*), H-1(C*) 4B 3.47 (t, J = 9.0 Hz) 76.2CH C-3(B*), C-5(B*), C-6(B*) H-2a(B*), H₃-6(B*) 5B 3.67 (dq, J = 9.0 and6.0 Hz) 73.3 CH C-1(B*), C-4(B*), C-6(B*) H-1(B*), H-3(B*), H₃-6(B*) 6B1.60 (d, J = 6.0 Hz) 18.9 CH₃ C-4(B*), C-5(B*) H-5(B*) 1C 4.79 (dd, J =9.6 and 2.0 Hz) 100.3 CH C-3(B*) H-3(B*), H-3(C*), H-5(C*) 2aC 2.42(ddd, J = 12, 12 and 9.6 Hz) 33.1 CH₂ C-1(C*), C-3(C*), C-4(C*) 2eC 2.18(ddd, J = 12, 5.0 and 2.0 Hz) 3C 4.21 (ddd, J = 12, 5.0 and 2.5 Hz) 77.0CH C-1(D*), C-4(C*) H-1(C*), H-5(C*), H-1(D*) 4C 4.10 (brd, J = 2.5 Hz)69.9 CH C-3(C*), C-5(C*) H-5(C*), H₃-6(C*) 5C 3.75 (dq, J = 6.2 and 2.5Hz) 72.1 CH C-1(C*), C-4(C*), C-6(C*) H-1(C*), H-3(C*), H-4(C*), 6C 1.54(d, J = 6.2 Hz) 17.5 CH₃ C-4(C*), C-5(C*) H-4(C*), H-5(C*) 1D 5.55 (dd,J = 9.6 and 2.0 Hz) 98.4 CH C-3(C*) H-2a(D*), H-2e(D*), H-5(D*), H-3(C*)2aD 1.89 (dd, J = 13.0 and 9.6 Hz) 45.5 CH₂ C-1(D*), C-3(D*), C-4(D*)H-1(D*), H-4(D*) 2eD 2.32 (dd, J = 13.0 and 2.0 Hz) H-1(D*) 3D — 71.2 CHH-1(D*) 4D 3.38 (d, J = 9.2 Hz) 77.7 CH C-3(D*), C-5(D*) H₃-3(D*),H₃-6(D*), H2a(D*) 5D 4.29 (dq, J = 9.2 and 6.0 Hz) 71.9 CH C-1(D*),C-4(D*), H-1(D*), H₃-6(D*) C-6(D*) 6D 1.61 (d, J = 6.0 Hz) 19.0 CH₃C-4(D*), C-5(D*) H-4(D*), H-5(D*) 3D-Me 1.50 (s) 28.2 CH₃ C-2(D*),C-4(D*), C-3(D*) H-4(D*) *A = B = C = D: sugars

TABLE 5 ¹H- and ¹³C-NMR data of demycarosyl-MTM [formula (XII)](Pyridine-d5, 400 MHz). ¹H-NMR, 400 MHz; δ in ¹³C-NMR, 100.6 MHz;Position ppm, multiplicity (J in Hz) δ in ppm Multiplicity HMBC NOESY 1— 204.4 C 2 4.95 d (11.6) 78.0 CH C-1, C-1C, C-3, C-4, H-1C, H-3, H-4a,H-4e C-1′ 3 3.48 (m) 42.6 C C-2, C-4, C-1′ H-2, H-4a, H-4e, H-1′ 4a 3.10dd (5.9 and 3.6) 28.5 CH2 C-2, C-3, C-1′ H-3, H-2 4e 3.26 dd (15.9 and13.0) H-3, H-2 4a — 137.2 C 5 7.04 (s) 102.1 CH C-6, C-8a, C-7, C-10H-10, H-1A, H-5A 6 — 160.5 C 7 — 111.7 C 7-CH3 2.47 (s) 9.1 CH3 C-6,C-7, C-8 8 — 156.9 C 8a — 109.3 C 9 — 165.7 C 9a — 108.8 C 10 6.63 (s)117.4 CH C-5, C-8a, C-9a, C- H-5, H-1A, H-4a, H-4e 10a 10a — 139.5 C 1′5.47 d (1.2) 83.0 CH C-2, C-3, C-4, 1′- H-2, H-3, 1′-OCH₃ OCH₃, C-2′1′-OCH3 3.69 (s) 59.2 C-1′, C-2′, C-3 2′ — 213.5 C 3′ 4.69 d (2.8) 81.2CH C-2′, C-4′, C-5′ H-4′, H-5′ 4′ 4.84 dq (6.2 and 2.8) 69.5 CH C-2′,C-3′, C-5′ H-5′, H-3′ 5′ 1.58 d (6.2) 20.8 CH3 C-3′, C-4′ H-4′, H-3′ 1A5.68 dd (9.6 and 2.0) 97.9 CH C-6 H-2Ae, H-3A, H-5A, H-5, H-10 2Aa 2.25ddd (12, 12 and 9.6) 37.8 CH₂ C-1A, C-3A, C-4A H-2Ae, H-4A, 2Ae 2.72 ddd(12, 5.0 and 2.0) H-1A, H-3A, H-2Aa 3A 4.29 ddd (12, 9.0 and 5.0) 80.1CH2 C-1B, C-4A H-1A, H-1B, H-5A, H-2Ae 4A 3.62 t (9.0) 75.9 CH C-3A,C-5A, C-6A H-2aA, H₃-6A 5A 4.02 dq (9.0 and 6.0) 73.7 CH C-1A, C-3A,C-4A, H-1A, H-3A, H₃-6A C-6A 6A 1.70 d (6.0) 19.2 CH₃ C-4A, C-5A H-4A,H-5A 1B 5.05 dd (9.6 and 2.0) 99.3 CH C-3A, H-2Be, H-3A, H-3B, H-5B 2Ba2.17 ddd (12, 12 and 9.6) 41.4 CH₂ C-1B, C-3B, C-4B H-2Be, H-4B, 2Be2.64 ddd (12, 5.0 and 2.0) H-1B, H-3B, H-2Ba 3B 4.14 ddd (12, 9.0 and5.0) 72.2 CH C-4B H-1B, H-2Be, H-5B 4B 3.58 t (9.0) 78.5 CH C-3B, C-5B,C-6B H-2Ba, H₃-6B 5B 3.75 dq (9.0 and 6.0) 72.5 CH C-1B, C-3B, C-4B, C-H-1B, H-3B, H₃-6B 6B 6B 1.64 d (6.0) 19.1 CH₃ C-4B, C-5B H-4B, H-5B 1C5.39 dd (J = 9.6 and 2.0z) 101.8 CH C-2 H-2, H-3C, H-5C, H-2Ce 2Ca 2.00ddd (12, 12 and 9.6) 38.5 CH₂ C-1C, C-3C, C-4C H-2Ce, H-4C, 2Ce 2.96 ddd(12, 5.0 and 2.0) H-1C, H-3C, H-2Ca 3C 4.06 ddd (12, 9.0 and 5.0) 81.5CH C-1D, C-4C H-1C, H-1D, H-5C, H-2Ce 4C 3.47 t (9.0) 76.3 CH C-3C,C-5C, C-6C H-2aC, H₃-6C 5C 3.68 dq (9.0 and 6.0) 73.4 CH C-1C, C-4C,C-6C H-3C, H-1C, H₃-6C 6C 1.61 d (6.0) 18.9 CH₃ C-4C, C-5C H-4C, H-5C 1D4.79 dd (9.6 and 2.0) 100.6 CH C-3C H-3C, H-3D, H-5D, H-2e-D 2Da 2.44ddd (12, 12 and 9.6) 36.4 CH₂ C-1D, C-3D, C-4D H-2De, H-4D, 2De 2.30 ddd(12, 5.0 and 2.0) H-1D, H-3D, H-2Da 3D 4.18 ddd (12, 5.0 and 2.5) 70.0CH C-2D, C-4D H-1D, H-2De, H-5D 4D 3.92 brd (2.5) 71.2 CH C-3D, C-5DH₃-6D 5D 3.73 dq (6.0 and 2.5) 73.8 CH C-4D, C-6D H-1D, H-3D, H₃-6D 6D1.57 d (6.0) 17.7 CH₃ C-4D, C-5D H-4D, H-5D *A = B = C = D: sugars

TABLE 6 ¹H- and ¹³C-NMR data of 6-dediolivosyl-6-β-D-amicetosyl-MTM[formula (XIII)] (Pyridine-d5, 400 MHz). ¹H-NMR, ¹³C-NMR, 400 MHz; δ inppm, 100.6 MHz; Position multiplicity (J in Hz) δ in ppm MultiplicityHMBC NOESY 1 — 204.4 C 2 4.95 d (11.6) 78.0 CH C-1, C-1C, C-3, C-4, C-1′H-1C, H-3, H-4a, H-4e 3 3.48 (m) 42.5 C C-2, C-4, C-1′ H-2, H-4a, H-4e,H-1′ 4a 3.12 dd (15.9 and 3.6) 28.3 CH₂ C-2, C-3, C-1′ H-3, H-2 4e 3.30dd (15.9 and 13.0) H-3, H-2 4a — 137.1 C 5 7.05 (s) 102.2 CH C-6, C-8a,C-7, C-10 H-10, H-1A, H-5A 6 — 160.6 C 7 — 111.7 C 7-CH₃ 2.45 (s) 9.1CH₃ C-6, C-7, C-8 8 — 156.9 C 8a — 109.3 C 9 — 165.8 C 9a — 108.7 C 106.65 (s) 117.4 CH C-5, C-8a, C-9a, C-10a H-5, H-1A, H-4a, H-4e 10a —139.5 C 1′ 5.49 d (1.2) 83.0 CH C-2, C-3, C-4, 1′-OCH₃, C-2′ H-2, H-3,1′-OCH₃ 1′-OCH₃ 3.69 (s) 59.1 CH₃ C-1′, C-2′, C-3 2′ — 213.7 C 3′ 4.70 d(2.8) 81.3 CH C-2′, C-4′, C-5′ H-4′, H-5′ 4′ 4.85 dq (6.2 and 2.8) 69.5CH C-2′, C-3′, C-5′ H-5′, H-3′ 5′ 1.59 d (6.2) 20.9 CH₃ C-3′, C-4′ H-4′,H-3′ 1A 5.60 dd (8.64 and 2.5) 98.4 CH C-6 H-2Aa, H-3Aa, H-5, H-5A, 2Aa2.12 (m) 32.0 CH₂ C-1A, C-3A, C-4A H-1A, H-4A, H-2Ae 2Ae H-1A, H-2Aa,H-3Aa 3Aa 1.97 (m) 31.4 CH₂ C-2A, C-4A H-1A, H-5A, H-3Ae 3Ae 2.35 (m)H-3Aa, H₃-6A 4A 3.67 (m) 71.3 CH C-3A, C-5A, C-6A H-2Aa, H₃-6A 5A 4.00dq (8.5 and 6.0) 77.8 CH C-1A, C-3A, C-4A, C-6A H-1A, H-3Aa, H₃-6A 6A1.67 d (6.0) 19.4 CH₃ C-4A, C-5A H-4A, H-5A 1C 5.39 dd (9.6 and 2.0)101.8 CH C-2 H-2, H-2Ce, H-3C, H-5C 2Ca 2.02 ddd (12, 12 and 9.6) 38.5CH₂ C-1C, C-3C, C-4C H-4C 2Ce 2.99 ddd (12, 5.0 and 2.0) H-1C 3C 4.05ddd (12, 9.0 and 5.0) 81.5 CH C-1D, C-4C H-1C, H-1D, H-5C, H-2Ce 4C 3.46t (9.0) 76.2 CH C-3C, C-5C, C-6C H-2Ca, H₃-6C 5C 3.68 dq (9.0 and 6.0)73.3 CH C-1C, C-4C, C-6C H-1C, H-3C, H₃-6C 6C 1.61 d (6.0) 19.5 CH₃C-4C, C-5C H-4C, H-5C 1D 4.79 dd (9.6 and 2.0) 100.3 CH C-3C H-3C, H-3D,H-2De, H-5D 2Da 2.42 ddd (12, 12 and 9.6) 33.1 CH₂ C-1D, C-3D, C-4D 2De2.22 ddd (12, 5.0 and 2.0) H-1D 3D 4.22 ddd (12, 5.0 and 2.5) 77.0 CHC-1E, C-4D H-1E, H-1D, H-2De, H-5D 4D 4.10 br.d (2.5) 70.0 CH C-3D, C-5DH₃-6D 5D 3.75 dq (6.0 and 2.5) 72.2 CH C-1D, C-4D, C-6D H-1D, H-3D,H₃-6D 6D 1.54 d (6.0) 17.6 CH₃ C-4D, C-5D H-5D 1E 5.55 dd (9.6 and 2.0)99.6 CH C-3D H-5E, H-3D, H-2Ea, H-2Ee 2Ea 1.86 dd (13.1 and 9.6) 45.6CH₂ C-1E, C-3E, C-4E H-4E, H-2Ee 2Ee 2.33 dd (13.1 and 2.0) H-1E, H-2Ea3E — 71.3 C — 3E-CH₃ 1.58 (s) 28.2 CH₃ C-2E, C-4E, C-3E H-4E 4E 3.37 d(9.2) 77.8 CH C-3E, C-5E H-2aE, H₃-3E, H₃-6E 5E 4.28 dq (9.2 and 6.0)72.9 CH C-1E, C-4E, H-1E, H₃-6E C-6E 6E 1.61 d (6.0) 19.1 CH₃ C-4E, C-5EH-5E *A = B = C = D = E: sugars

TABLE 7 ¹H- and ¹³C-NMR data ofdeoliosyl-demycarosyl-3C-β-D-boivinosyl-MTM [formula (XVII)](Pyridine-d5, 400 MHz). ¹³C-NMR, ¹H-NMR, 400 MHz; δ in 100.6 MHz;Position ppm, multiplicity (J in Hz) δ in ppm Multiplicity HMBC NOESY 1— 204.5 C 2 4.94 d (11.6) 77.6 CH C-1, C-1C, C-3, C-4, C-1′ H-1C, H-3,H-4a, H-4e 3 3.48 (m) 42.6 C C-2, C-4, C-1′ H-2, H-4a, H-4e, H-1′ 4a3.10 dd (15.9 and 3.6) 28.1 CH2 C-2, C-3, C-1′ H-3, H-2 4e 3.26 dd (15.9and 13.0) H-3, H-2 4a — 137.2 C 5 7.04 (s) 102.2 CH C-6, C-8a, C-7, C-10H-10, H-1A, H-5A 6 — 160.4 C 7 — 111.9 C 7-CH₃ 2.47 (s) 9.1 CH3 C-6,C-7, C-8 8 — 157.0 C 8a — 109.4 C 9 — 165.8 C 9a — 108.9 C 10 6.62 (s)117.0 CH C-5, C-8a, C-9a, C-10a H-5, H-1A, H-4a, H-4e 10a — 139.5 C 1′5.46 d (1.2) 83.0 CH C-2, C-3, C-4, 1′-OCH₃, C-2′ H-2, H-3, 1′-OCH₃1′-OCH₃ 3.69 (s) 59.2 C-1′, C-2′, C-3 2′ — 213.5 C 3′ 4.69 d (2.8) 81.2CH C-2′, C-4′, C-5′ H-4′, H-5′ 4′ 4.84 dq (6.0 and 2.8) 69.5 CH C-2′,C-3′, C-5′ H-5′, H-3′ 5′ 1.59 d (6.0) 20.8 CH3 C-3′, C-4′ H-4′, H-3′ 1A5.67 dd (9.6 and 2.0) 97.9 CH C-6 H-3A, H-5A, H-2Aa, H-2Ae, H-5, H-102Aa 2.23 ddd (12.0, 12.0 and 9.6) 37.8 CH₂ C-1A, C-3A, C-4A H-1A, H-4A,H-2Ae 2Ae 2.70 ddd (12.0, 5.0 and 2.0) H-1A, H-3A, H-2Aa 3A 4.27 ddd(12, 9.2 and 5.0) 74.2 CH2 C-1B, C-4A H-1A H-1B, H-5A, H-2Ae 4A 3.61 t(9.2) 80.1 CH C-3A, C-5A, C-6A H-2Aa, H₃-6A 5A 4.01 dq (9.2 and 6.0)73.8 CH C-1A, C-3A, C-4A, H-1A, H-3A, C-6A H₃-6A 6A 1.71 d (J = 6.0)19.2 CH₃ C-4A, C-5A H-4A, H-5A 1B 5.05 dd (9.6 and 2.0) 99.4 CH C-3AH-2Ba, H-2Be, H-3A, H-3B, H-5B 2Ba 2.14 ddd (12, 12 and 9.6) 41.4 CH₂C-1B, C-3B, C-4B H-1B, H-4B 2Be 2.64 ddd (12, 5.0 and 2.0) H-1B 3B 4.14ddd (12, 9.0 and 5.0) 72.2 CH C-4B H-2Be, H-1B, H-5B 4B 3.57 t (9.0)78.5 CH C-3B, C-5B, C-6B H-2Ba, H₃-6B 5B 3.73 dq (9.0 and 6.0) 73.4 CHC-1B, C-3B, C-4B, H-1B, H-3B, H₃-6B C-6B 6B 1.63 d (6.0) 19.1 CH₃ C-4B,C-5B H-5B 1C 5.38 dd (9.6 and 2.0) 101.8 CH C-2 H-2, H-3C, H-5C, H-2Ce2Ca 2.00 ddd (12, 12 and 9.6) 38.2 CH₂ C-1C, C-3C, C-4C H-4C 2Ce 2.92ddd (12, 5.0 and 2.0) H-1C 3C 4.05 ddd (12, 9.0 and 5.0) 81.5 CH C-1D,C-4C H-1C, H-1D, H-5C, H-2Ce 4C 3.47 t (9.0) 76.0 CH C-3C, C-5C, C-6CH-2Ca, H₃-6C 5C 3.67 dq (9.0 and 6.0) 73.6 CH C-4C, C-6C H-3C, H-1C,H₃-6C 6C 1.60 d (6.0) 18.9 CH₃ C-4C, C-5C H-5C, H-4C 1D 5.54 dd (10.0and 3.0) 99.4 CH C-3C H-3D, H-5D, H-2De, H-3C 2Da 2.55 ddd (13, 10 and3.0) 41.4 CH₂ C-1D, C-3D, C-4D H-1D, H-2De 2De 2.28 ddd (13, 3.0 and3.0) 3D 3.77 ddd (3.2, 3.0 and 1.2) 71.4 CH C-4D H-2Da, H-4D, H₃-6D,H-5D 4D 3.87 dd (3.2 and 1.2) 71.0 CH C-3D, C-5D H-3D, H-5D, H₃-6D 5D4.64 dq (6.0 and 3.2) 70.3 CH C-1D, C-4D, C-6D H-1D, H-3D, H₃-6D 6D 1.57d (6.0) 17.6 CH₃ C-4D, C-5D H-4D, H-5D, H-3D *= B = C = D: sugars

TABLE 8 ¹H- and ¹³C-NMR data of6-dediolivosyl-6-β-D-amicetosyl-deoliosyl-demycarosyl-3C-β-D-boivinosyl-MTM[formula (XVIII)] (Pyridine-d5, 400 MHz). ¹H-NMR, 400 MHz; δ in ppm,multiplicity ¹³C-NMR, 100.6 MHz; Position (J in Hz) δ in ppmMultiplicity HMBC NOESY 1 — 204.3 C 2 4.38 d (11.6) 78.1 CH C-1, C-1C,C-3, C- H-1C, H-3, H-4a, H-4e 4, C-1′ 3 3.46 (m) 42.6 C C-2, C-4, C-1′H-2, H-4a, H-4e, H-1′ 4a 3.11 dd (15.9 and 3.6) 26.8 CH2 C-2, C-3, C-1′H-3, H-2 4e 3.27 dd (15.9 and 13.0) H-3, H-2 4a — 137.1 C 5 7.04 (s)102.3 CH C-6, C-8a, C-7, C- H-10, H-1A, H-5A 10 6 — 160.6 C 7 — 111.7 C7-CH3 2.45 (s) 9.19 CH3 C-6, C-7, C-8 8 — 156.9 C 8a — 109.3 C 9 — 165.8C 9a — 108.7 C 10 6.64 (s) 117.9 CH C-5, C-8a, C-9a, C- H-5, H-1A, H-4a,H-4e 10a 10a — 139.5 C 1′ 5.48 d (1.2) 83.1 CH C-2, C-3, C-4, 1′- H-2,H-3, 1′-OCH₃ OCH₃, C-2′ 1′-OCH3 3.70 (s) 59.2 C-1′, C-2′, C-3 2′ — 213.6C 3′ 4.70 d (2.8) 81.3 CH C-2′, C-4′, C-5′ H-4′, H-5′ 4′ 4.84 dq (6.2and 2.8) 69.5 CH C-2′, C-3′, C-5′ H-5′, H-3′ 5′ 1.60 (d, J = 6.2) 20.8CH3 C-3′, C-4′ H-4′, H-3′ 1A 5.59 (dd, J = 9.6 and 2.0) 99.6 CH C-6H-2Aa, H-3Aa, H-5, H-5A, 2Aa 2.15 (m) 31.4 CH₂ C-1A, C-3A, C-4A H-1A,H-4A, H-2Ae 2Ae 2.41 (m) H-1A, H-2Aa, H-3Aa 3Aa 1.97 (m) 32.1 CH2 C-2A,C-4A H-1A, H-5A, H-3Ae 3Ae 2.38 (m) H-3Aa, H₃-6A 4^(a) 3.68 (m) 71.3 CHC-3A, C-5A, C-6A H-2Aa, H₃-6A 5^(a) 4.01 dq (9.0 and 6.0) 77.89 CH C-1A,C-3Aa, C- H-1A, H-3Aa, H₃-6A 4A, C-6A 6A 1.67 d (6.0) 19.4 CH₃ C-4A,C-5A H-4A, H-5A 1C 5.38 dd (9.6 and 2.0) 101.8 CH C-2 H-2, H-2Ce, H-3C,H-5C 2Ca 2.00 ddd (12, 12 and 9.6) 38.6 CH₂ C-1C, C-3C, C-4C H-4C 2Ce2.93 ddd (12, 5.0 and 2.0) H-1C 3C 4.02 ddd (12, 9.0 and 5.0) 81.4 CHC-1D, C-4C H-1C, H-1D, H-4C, H-5C, H- 2Ce 4C 3.45 t (9.0) 76.3 CH C-3C,C-5C, C-6C H-2Ca, H₃-6C 5C 3.67 dq (9.0 and 6.0) 73.4 CH C-1C, C-4C,C-6C H-1C, H-3C, H₃-6C 6C 1.61 d (6.0) 19.1 CH₃ C-4C, C-5C H-4C, H-5C 1D4.72 dd (10 and 2.0) 102.0 CH C-3C H-3C, H-2De, H-5D 2Da 2.26 ddd (13,10 and 3.0) 31.45 CH₂ C-1D, C-3D, C-4D H-1D, H-2De 2De 1.71 ddd (13, 3.0and 2.0) 3D 3.71 ddd (3.0, 3.0 and 1.2) 66.2 CH C-4D H-2Da, H-4D, H₃-6D,H-5D 4D 3.65 dd (2.5, and 1.2) 71.3 CH C-3D, C-5D H-3D, H-5D, H₃-6D 5D3.78 dq (6.0 and 2.5) 75.58 CH C-1D, C-4D, C-6D H-1D, H-3D, H₃-6D 6D1.48 d (6.0) 18.14 CH₃ C-4D, C-5D H-4D, H-5D, H-3D *A = B = C = D:sugars

TABLE 9 ¹H- and ¹³C-NMR data ofdeoliosyl-demycarosyl-3C-β-D-olivosyl-3D-β-D-digitoxosyl-MTM [formula(XIX)] (Pyridine-d5, 400 MHz). ¹H-NMR, 400 MHz; δ in ppm, multiplicity¹³C-NMR, 100.6 MHz; Position (J in Hz) δ in ppm Multiplicity HMBC NOESY1 — 204.4 C 2 4.96 d (11.6) 77.9 CH C-1, C-1C, C-3, C-4, C- H-1C, H-3,H-4a, H-4e 1′ 3 3.48 (m) 42.6 C C-2, C-4, C-1′ H-2, H-4a, H-4e, H-1′ 4a3.10 dd (15.9 and 3.6) 28.1 CH2 C-2, C-3, C-1′ H-3, H-2 4e 3.27 dd (15.9and 13.0) H-3, H-2 4a — 137.1 C 5 7.05 (s) 102.2 CH C-6, C-8a, C-7, C-10H-10, H-1A, H-5A 6 — 160.5 C 7 — 111.7 C 7-CH₃ 2.47 (s) 8.9 CH3 C-6,C-7, C-8 8 — 157.0 C 8a — 109.3 C 9 — 165.8 C 9a — 108.8 C 10 6.63 (s)117.4 CH C-5, C-8a, C-9a, C-10a H-5, H-1A, H-4a, H-4e 10a — 139.5 C 1′5.49 d (1.2) 82.9 CH C-2, C-3, C-4, 1′-OCH₃, H-2, H-3, 1′-OCH₃ C-2′1′-OCH₃ 3.71 (s) 59.5 C-1′, C-2′, C-3 2′ — 213.4 C 3′ 4.70 d (2.8) 81.1CH C-2′, C-4′, C-5′ H-4′, H-5′ 4′ 4.84 dq (6.2 and 2.8) 69.3 CH C-2′,C-3′, C-5′ H-5′, H-3′ 5′ 1.59 d (6.2) 20.6 CH3 C-3′, C-4′ H-4′, H-3′ 1A5.67 dd (9.6 and 2.0) 97.9 CH C-6 H-3A, H-5A, H-2Aa, H-2Ae, H-5, H-102Aa 2.25 ddd (12, 12 and 9.6) 37.7 CH₂ C-1A, C-3A, C-4A H-1A, H-4A,H-2Ae 2Ae 2.71 ddd (12, 5.0 and 2.0) H-1A, H-3A, H-2Aa 3A 4.28 ddd (12,9.0 and 5.0) 80.5 CH2 C-1B, C-4A H-1A, H-1B, H-5A, H-2Ae 4A 3.62 t (9.0)75.8 CH C-3A, C-5A, C-6A H-2Aa, H₃-6A 5A 4.01 dq (9.0 and 6.0) 73.6 CHC-1A, C-3A, C-4A, H-1A, H-3A, C-6A H₃-6A 6A 1.70 d (6.0) 19.0 CH₃ C-4A,C-5A H-4A, H-5A 1B 5.05 dd (9.6 and 2.0) 99.4 CH C-3A H-2Ba, H-2Be,H-3A, H- 3B, H-5B 2Ba 2.14 ddd (12, 12 and 9.6) 41.2 CH₂ C-1B, C-3B,C-4B H-1B, H-4B 2Be 2.65 ddd (12, 5.0 and 2.0) H-1B 3B 4.16 ddd (12, 9.0and 5.0) 72.2 CH C-4B H-2Be, H-1B, H-5B 4B 3.57 t (9.0) 77.6 CH C-3B,C-5B, C-6B H-2Ba, H₃-6B 5B 3.74 dq (9.0 and 6.0) 73.7 CH C-1B, C-3B,C-4B, H-1B, H-3B, H₃-6B C-6B 6B 1.64 d (6.0) 18.3 CH₃ C-4B, C-5B H-5B 1C5.39 dd (9.6 and 2.0) 101.6 CH C-2 H-2, H-3C, H-5C, H-2Ce 2Ca 2.00 ddd(12, 12 and 9.6) 38.4 CH₂ C-1C, C-3C, C-4C H-4C 2Ce 3.00 ddd (12, 5.0and 2.0) H-1C 3C 4.10 ddd (12, 9.0 and 5.0) 81.0 CH C-1D, C-4C H-1C,H-1D, H-5C, H-2Ce 4C 3.50 t (9.0) 76.1 CH C-3C, C-5C, C-6C H-2Ca, H₃-6C5C 3.69 dq (9.0 and 6.0) 73.6 CH C-4C, C-6C H-3C, H-1C, H₃-6C 6C 1.60 d(6.0) 18.9 CH₃ C-4C, C-5C H-5C, H-4C 1D 4.90 dd (9.6 and 2.0) 99.4 CHC-3C H-3D, H-5D, H-2De, H-3C 2Da 1.90 ddd (12, 12 and 9.6) 32.3 CH₂C-1D, C-3D, C-4D 2De 2.18 ddd (12, 5.0 and 2.0) H-1D 3D 4.04 ddd (12,9.0 and 5.0) 80.1 CH C-1E, C-4D H-1D, H-2De, H-5D, H-1E 4D 3.44 T (9.0)75.8 CH C-3D, C-5D H-2Da, H₃-6D 5D 3.66 dq (9.0 and 6.0) 73.3 CH C-4D,C-6D H-1D, H-3D, H₃-6D 6D 1.58 d (6.0) 18.7 CH₃ C-4D, C-5D H-4D, H-5D 1E4.88 dd (10 and 2.0) 101.3 CH C-3D H-5E, H-2Ea, H-2Ee, H-3D 2Ea 1.75 ddd(13, 10.0 and 2.5) 31.1 CH₂ C-1E, C-3E, C-4E 2Ee 2.21 ddd (13, 2.5 and2.0) H-1E, H-2Ea 3E 3.52 ddd (2.8, 2.5, and 2.5) 71.3 CH C-4E H-4E 4E3.49 dd (9.0 and 2.8) 77.6 CH C-3E, C-5E H-2Ea, H-3E, H₃-6E 5E 3.66 dq(9.0 and 6.0) 73.3 CH C-1E, C-4E, C-6E H₃-6E, H-1E 6E 1.55 d (6.0) 18.6CH₃ C-4E, C-5E H-5E *A = B = C = D = E: sugars

TABLE 10 ¹H- and ¹³C-NMR data of6-dediolivosyl-6-β-D-amicetosyl-deoliosyl-demycarosyl-3C-β-D-olivosyl-3D-β-D-digitoxosyl-MTM[(formula XX)] (Pyridine-d5, 400 MHz). ¹³C-NMR, ¹H-NMR, 400 MHz; δ inppm, 100.6 MHz; δ Position multiplicity (J in Hz) in ppm MultiplicityHMBC NOESY 1 — 204.3 C 2 4.95 d (11.6) 78.0 CH C-1, C-1C, C-3, C-4, C-1′H-1C, H-3, H-4a, H-4e 3 3.48 (m) 42.6 C C-2, C-4, C-1′ H-2, H-4a, H-4e,H-1′ 4a 3.10 dd (15.9 and 3.6) 28.3 CH₂ C-2, C-3, C-1′ H-3, H-2 4e 3.27dd (15.9 and 13.0) H-3, H-2 4a — 137.1 C 5 7.05 (s) 102.2 CH C-6, C-8a,C-7, C-10 H-10, H-1A, H-5A 6 — 160.6 C 7 — 111.7 C 7-CH3 2.45 (s) 9.1CH₃ C-6, C-7, C-8 8 — 156.9 C 8a — 109.3 C 9 — 165.9 C 9a — 108.7 C 106.66 (s) 117.4 CH C-5, C-8a, C-9a, C-10a H-5, H-1A, H-4a, H-4e 10a —139.5 C 1′ 5.49 d (1.2) 83.1 CH C-2, C-3, C-4, 1′-OCH₃, C-2′ H-2, H-3,1′-OCH₃ 1′-OCH3 3.71 (s) 59.2 CH₃ C-1′, C-2′, C-3 2′ — 213.6 C 3′ 4.71 d(2.8) 81.3 CH C-2′, C-4′, C-5′ H-4′, H-5′ 4′ 4.84 dq (6.2 and 2.8) 69.5CH C-2′, C-3′, C-5′ H-5′, H-3′ 5′ 1.59 d (6.2) 20.8 CH₃ C-3′, C-4′ H-4′,H-3′ 1A 5.59 dd (8.64 and 2.5) 99.7 CH C-6 H-2Aa, H-3Aa, H-5, H-5A, 2Aa2.17 (m) 31.4 CH₂ C-1A, C-3A, C-4A H-1A, H-4A, H-2Ae 2Ae 2.43 (m) H-1A,H-2Aa, H-3Aa 3Aa 1.96 (m) 32.1 CH₂ C-2A, C-4A H-1A, H-5A, H-3Ae 3Ae 2.40(m) H-3Aa, H₃-6A 4A 3.69 (m) 71.3 CH C-3A, C-5A, C-6A H-2Aa, H₃-6A 5A4.02 dq (8.5 and 6.0) 77.7 CH C-1A, C-3A, C-4A, C-6A H-1A, H-3Aa, H₃-6A6A 1.67 d (6.0) 19.4 CH₃ C-4A, C-5A H-4A, H-5A 1C 5.39 dd (9.6 and 2.0)101.7 CH C-2 H-2, H-3C, H-5C, H-2Ce 2Ca 2.00 ddd (12, 12 and 9.6) 38.4CH₂ C-1C, C-3C, C-4C H-4C 2Ce 2.99 ddd (12, 5.0 and 2.0) H-1C 3C 4.10ddd (12, 9.0 and 5.0) 81.1 CH C-1D, C-4C H-1C, H-1D, H-5C, H-2Ce 4C 3.49t (9.0) 76.2 CH C-3C, C-5C, C-6C H-2Ca, H₃-6C 5C 3.68 dq (9.0 and 6.0)73.4 CH C-4C, C-6C H-3C, H-1C, H₃-6C 6C 1.61 d (6.0) 19.1 CH₃ C-4C, C-5CH-5C, H-4C 1D 4.90 dd (9.6 and 2.0) 99.3 CH C-3C H-3D, H-5D, H-2De, H-3C2Da 1.90 ddd (12, 12 and 9.6) 32.5 CH₂ C-1D, C-3D, C-4D 2De 2.50 ddd(12, 5.0 and 2.0) H-1D 3D 4.03 ddd (12, 9.0 and 5.0) 80.5 CH C-1E, C-4DH-1D, H-2De, H-5D, H-1E 4D 3.47 t (9.0) 75.9 CH C-3D, C-5D H-2Da, H₃-6D5D 3.68 dq (9.0 and 6.0) 73.3 CH C-4D, C-6D H-1D, H-3D, H₃-6D 6D 1.55 d(6.0) 18.8 CH₃ C-4D, C-5D H-4D, H-5D 1E 4.88 dd (9.6 and 2.0) 101.35 CHC-3D H-5E, H-2Ea, H-2Ee, H-3D 2Ea 1.77 ddd (13, 10 and 2.5) 31.1 CH₂C-1E, C-3E, C-4E 2Ee 2.20 ddd (13, 2.5 and 2.0) H-1E, H-2Ea 3E 3.52 ddd(2.8, 2.5 and 2.5) 71.3 CH C-4E H-4E 4E 3.45 dd (9.0, 2.8) 71.9 CH C-3E,C-5E H-2Ea, H-3E, H₃-6E 5E 3.68 dq (6.0 and 9.0) 73.4 CH C-1E, C-4E,C-6E H₃-6E, H-1E 6E 1.58 d (6.0) 19.1 CH₃ C-4E, C-5E H-5E *A = B = C = D= E: sugars

TABLE 11 ¹H- and ¹³C-NMR data of6-dediolivosyl-6-β-D-amicetosyl-deoliosyl-3C-β-D-olivosyl-MTM [formula(XXI)] (Pyridine-d5, 400 MHz). ¹³C-NMR, ¹H-NMR, 400 MHz; δ in ppm, 100.6MHz; δ Position multiplicity (J in Hz) in ppm Multiplicity HMBC NOESY 1— 204.3 C 2 4.95 d (11.6) 78.0 CH C-1, C-1C, C-3, C-4, C-1′ H-1C, H-3,H-4a, H-4e 3 3.47 (m) 42.6 C C-2, C-4, C-1′ H-2, H-4a, H-4e, H-1′ 4a3.11 dd (15.9 and 3.6) 28.1 CH₂ C-2, C-3, C-1′ H-3, H-2 4e 3.27 dd (15.9and 13.0) H-3, H-2 4a — 136.4 C 5 7.05 (s) 102.2 CH C-6, C-8a, C-7, C-10H-10, H-1A, H-5A 6 — 160.6 C 7 — 111.7 C 7-CH₃ 2.45 (s) 9.1 CH₃ C-6,C-7, C-8 8 — 156.9 C 8a — 109.3 C 9 — 165.9 C 9a — 108.7 C 10 6.65 (s)117.4 CH C-5, C-8a, C-9a, C-10a H-5, H-1A, H-4a, H-4e 10a — 139.5 C 1′5.50 d (1.2) 83.1 CH C-2, C-3, C-4, 1′-OCH₃, C-2′ H-2, H-3, 1′-OCH₃1′-OCH₃ 3.71 (s) 59.2 CH₃ C-1′, C-2′, C-3 2′ — 213.6 C 3′ 4.71 d (2.8)81.3 CH C-2′, C-4′, C-5′ H-4′, H-5′ 4′ 4.84 dq (6.2 and 2.8) 69.5 CHC-2′, C-3′, C-5′ H-5′, H-3′ 5′ 1.58 d (6.2) 20.8 CH₃ C-3′, C-4′ H-4′,H-3′ 1A 5.59 dd (8.64 and 2.5) 99.6 CH C-6 H-2Aa, H-3Aa, H-5, H-5A, 2Aa2.17 (m) 31.4 CH₂ C-1A, C-3A, C-4A H-1A, H-4A, H-2Ae 2Ae 2.43 (m) H-1A,H-2Aa, H-3Aa 3Aa 1.97 (m) 32.1 CH₂ C-2A, C-4A H-1A, H-5A, H-3Ae 3Ae 2.39(m) H-3Aa, H₃-6A 4A 3.69 (m) 71.3 CH C-3A, C-5A, C-6A H-2Aa, H₃-6A 5A4.03 dq (8.5 and 6.0) 77.8 CH C-1A, C-3A, C-4A, C-6A H-1A, H-3Aa, H₃-6A6A 1.67 d (6.0) 19.4 CH₃ C-4A, C-5A H-4A, H-5A 1C 5.39 dd (9.6 and 2.0)101.7 CH C-2 H-2, H-2Ce, H-3C, H-5C 2Ca 2.02 ddd (12, 12 and 9.6) 38.4CH₂ C-1C, C-3C, C-4C H-4C 2Ce 2.99 ddd (12, 5.0 and 2.0) H-1C 3C 4.09ddd (12, 9.0 and 5.0) 81.1 CH C-1D, C-4C H-1C, H-1D, H-4C, H-5C, H- 2Ce4C 3.46 t (9.0) 76.2 CH C-3C, C-5C, C-6C H-2Ca, H₃-6C 5C 3.67 dq (9.0and 6.0) 73.4 CH C-1C, C-4C, C-6C H-1C, H-3C, H₃-6C 6C 1.61 d (6.0) 19.2CH₃ C-4C, C-5C H-4C, H-5C 1D 4.85 dd (9.6 and 2.0) 99.3 CH C-3C H-3C,H-3D, H-2De, H-5D 2Da 1.93 ddd (12, 12 and 9.6) 38.6 CH₂ C-1D, C-3D,C-4D H-1D 2De 2.40 ddd (12, 5.0 and 2.0) 3D 4.01 ddd (12, 9.0 and 5.0)81.0 CH C-1E, C-4D H-1E, H-1D, H-2De, H-5D 4D 3.46 t (9.0) 76.0 CH C-3D,C-5D H-2Da, H₃-6D 5D 3.69 dq (9.0 and 6.0) 73.4 CH C-1D, C-4D, C-6DH-1D, H-3D, H₃-6D 6D 1.55 d (6.0) 18.8 CH₃ C-4D, C-5D H-4D, H-5D 1E 5.46dd (9.6 and 2.0) 98.9 CH C-3D H-5E, H-3D, H-2Ea, H-2Ee 2Ea 1.85 dd (13.1and 9.6) 45.3 CH₂ C-1E, C-3E, C-4E H-4E, H-2Ee 2Ee 2.32 dd (13.1 and2.0) H-1E, H-2Ea 3E — 71.3 C — 3E-CH₃ 1.50 (s) 28.0 CH₃ C-4E, C-5E, C-3EH-5E, H₃-6E 4E 3.34 d (9.2) 77.5 CH C-3E-CH₃, C-3E, C-5E H-2aE, H₃-3E,H₃-6E 5E 4.28 dq (9.2 and 6.0) 72.2 CH C-3E, C-4E H₃-3E, H₃-6E 6E 1.60 d(6.0) 19.1 CH₃ C-1E, C-4E, H-1E, H₃-6E C-5E *A = B = C = D = E: sugars

TABLE 12 Antitumor activity assay of derivatives of MTM against tumorcell lines. Data obtained with MTM are also included as a reference. Thenumber values refer to GI₅₀ (μM), or concentration at which the compoundassayed inhibits 50% of the cell growth compared to non-treated cells.compounds Cell line (cancer type) MTM VIII IX X XI XII XIII XVII XVIIIXIX XX XXI MDA-MB-231 (breast) 0.16 0.23 1.94 0.37 0.45 1.28 1.38 3.720.40 0.69 >10 0.47 A549 (lung) 0.16 0.19 2.67 0.48 0.75 1.81 1.49 >100.75 0.91 >10 0.44 HT29 (colon) 0.21 0.27 3.87 0.93 0.71 >10 3.19 >102.01 5.98 >10 0.94 VIII = demycarosyl-3D-β-D-digitoxosyl-MTM; IX =deoliosyl-3C-α-L-digitoxosyl-MTM; X = deoliosyl-3C-β-D-mycarosyl-MTM; XI= 3A-deolivosyl-MTM; XII = demycarosyl-MTM; XIII =6-dediolivosyl-6-β-D-amicetosyl-MTM; XVII =deoliosyl-demycarosyl-3C-β-D-boivinosyl-MTM; XVIII =6-dediolivosyl-6-β-D-amicetosyl-deoliosyl-demycarosyl-3C-β-D-boivinosyl-MTM;XIX = deoliosyl-demycarosyl-3C-β-D-olivosyl-3D-β-D-digitoxosyl-MTM; XX =6-dediolivosyl-6-β-D-amicetosyl-deoliosyl-demycarosyl-3C-β-D-olivosyl-3D-β-D-digitoxosyl-MTM;XXI = 6-dediolivosyl-6-β-D-amicetosyl-deoliosyl-3C-β-D-olivosyl-MTM

1. A compound with formula (I)

wherein R1 can be hydrogen, hydroxyl (OH), a hydroxyl group protectedwith a protecting group or a monosaccharide of formula

and R2 can be selected between the following group of substituents:

providing that when R1 is

R2 is not


2. The compound of claim 1, with formula VIII:


3. The compound of claim 1, with formula IX:


4. The compound of claim 1, with formula X:


5. The compound of claim 1, with formula XI:


6. The compound of claim 1, with formula XII:


7. The compound of claim 1, with formula XIII:


8. The compound of claim 1, with formula XVII:


9. The compound of claim 1, with formula XVIII:


10. The compound of claim 1, with formula XIX:


11. The compound of claim 1, with formula XX:


12. The compound of claim 1, with formula XXI:


13. A bacterial strain Streptomyces argillaceus (pFL942) or Streptomycesargillaceus M7U1 (pFL845) characterized by having an additional nucleicacid encoding active enzymes for the biosynthesis of sugars which arenot present in Streptomyces argillaceus wild type.
 14. A bacterialstrain of claim 13, characterized in that the nucleic acid ofStreptomyces argillaceus (pFL942) is contained in the plasmid pFL942 andencodes active enzymes for the biosynthesis of L-mycarose andbiosynthetic intermediates thereof; and the nucleic acid of Streptomycesargillaceus M7U1 (pFL845) is contained in plasmid the pFL845 and encodesactive enzymes for the biosynthesis of D-amicetose and biosyntheticintermediates thereof.
 15. A method for obtaining the bacterial strainsof claim 13, comprising the introduction of plasmid pFL942 inStreptomyces argillaceus or the introduction of plasmid pFL845 inStreptomyces argillaceus M7U1 which encodes active enzymes for thebiosynthesis of sugars which are not present in Streptomyces argillaceuswild type.
 16. A method for producing derivatives of mithramycinaccording to formula I, comprising: a) culturing a bacterial strain ofclaim 13 in suitable medium; and b) isolating a derivative ofmithramycin according to formula I from the culture broth.